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AT A GLANCE COMMENTARY: 2 
Scientific Knowledge on the Subject: 3 
In the antiretroviral therapy era, community-acquired pneumonia (CAP) remains the 4 
commonest cause of adult hospitalisation and a major cause of mortality in many sub-5 
Saharan Africa HIV-affected countries. With the exception of cohorts from South Africa, 6 
contemporary studies describing CAP aetiology and outcome from the region are either 7 
small, retrospective or only use limited investigations to define aetiology. Current CAP 8 
management protocols applied in sub-Saharan Africa are therefore inadequately informed 9 
by contemporary data.  10 
What This Study Adds to the Field: 11 
In a large prospective cohort of hospitalised adults in Malawi we show that the major 12 
burden of hospitalised acute CAP remains in young, HIV-infected patients and that 13 
Streptococcus pneumoniae, tuberculosis and influenza predominate as the major causes. 14 
CAP mortality is high compared to populations from well-resourced settings with similar age 15 
profiles, and is associated with potentially modifiable risk factors including hypoxaemia. 16 
Death from CAP is poorly predicted by commonly used CAP severity-assessment tools such 17 
as CURB65. 18 
 19 
This article has an online data supplement, which is accessible from this issue's table of 20 
content online at www.atsjournals.org 21 
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ABSTRACT 1 
Rationale: In the context of rapid antiretroviral therapy (ART) rollout and an increasing 2 
burden of non-communicable diseases, there are few contemporary data describing the 3 
aetiology and outcome of community-acquired pneumonia (CAP) in sub-Saharan Africa.  4 
Objectives: To describe the current aetiology of CAP in Malawi and identify risk factors for 5 
mortality. 6 
Methods: We conducted a prospective observational study of adults hospitalised with CAP 7 
to a teaching hospital in Blantyre, Malawi. Aetiology was defined by blood culture, 8 
Streptococcus pneumoniae urinary antigen detection, sputum mycobacterial culture and 9 
Xpert MTB/RIF, and nasopharyngeal aspirate multiplex PCR.  10 
Measurements and Main Results: In 459 patients (285 [62.1%] males; median age 34.7 [IQR: 11 
29.4-41.9] years), 30-day mortality was 14.6% (64/439) and associated with male sex 12 
(adjusted odds ratio 2.60 [95% CI: 1.17-5.78]), symptom duration >7 days (2.78 [1.40-5.54]), 13 
tachycardia (2.99 [1.48-6.06]), hypoxaemia (4.40 [2.03-9.51]) and inability to stand (3.59 14 
[1.72-7.50]). HIV was common (355/453; 78.4%), frequently newly diagnosed (124/355; 15 
34.9%), but not associated with mortality. S. pneumoniae (98/458 [21.4%]) and 16 
Mycobacterium tuberculosis (75/326 [23.0%]) were the most frequently identified 17 
pathogens. Viral infection occurred in 32.6% (148/454) with influenza (40/454 [8.8%]) most 18 
common. Bacterial-viral co-infection occurred in 9.1% (28/307). Detection of M. tuberculosis 19 
was associated with mortality (aOR 2.44 [1.19-5.01]). 20 
Conclusions: In the ART era, CAP in Malawi remains predominantly HIV-associated with a 21 
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large proportion attributable to potentially vaccine-preventable pathogens. Strategies to 1 
increase early detection and treatment of tuberculosis and improve supportive care, in 2 
particular the correction of hypoxaemia, should be evaluated in clinical trials to address CAP-3 
associated mortality.  4 
Abstract word count: 250 5 
Keywords: community-acquired pneumonia; HIV; Africa South of the Sahara; Streptococcus 6 
pneumoniae; pulmonary tuberculosis 7 
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INTRODUCTION 1 
Globally, pneumonia is the commonest infectious cause of death and the second leading 2 
cause of overall life years lost (1). In sub-Saharan Africa alone, lower respiratory tract 3 
infections account for 390,000 deaths in older children and adults each year (2). Whilst the 4 
aetiology and outcome of community-acquired pneumonia (CAP) has been thoroughly 5 
described in large cohorts of adults in well-resourced settings in Europe and North America 6 
(3, 4) and more recently in young children (<5 years) from sub-Saharan Africa (5), 7 
contemporary data on acute CAP in adults from sub-Saharan Africa are limited. With the 8 
exception of cohorts from South Africa (6, 7), recent studies are either small (8, 9), 9 
retrospective (10) or only use a restricted panel of investigations to define aetiology (11). 10 
In Malawi – a very low-income country in Southern Africa – pneumonia is the commonest 11 
cause of adult hospitalisation (12). There is a generalised HIV epidemic (adult prevalence 12 
10.6% (13)) and high tuberculosis (TB) incidence (159 cases per 100,000 population (14)). 13 
These factors create a backdrop distinct from most well-resourced settings and common to 14 
many countries in the region, that is likely to have a substantial bearing on the epidemiology 15 
and aetiology of CAP; more comprehensive data are therefore crucial to develop appropriate 16 
context-specific management guidelines (15). Given the continued rollout of antiretroviral 17 
therapy (ART) (16), recent introduction of infant pneumococcal conjugate vaccination (PCV) 18 
(17) and the broader context of rapidly increasing life expectancy and emergence of chronic 19 
non-communicable diseases (18), contemporaneous data are vital. We therefore conducted 20 
a prospective study of adults hospitalised with CAP to the largest central hospital in Malawi 21 
to describe aetiology and to identify risk factors for mortality to inform the development of 22 
local guidelines for antibiotic choice and severity assessment. Some of the results of this 23 
study have been previously reported in the form of abstracts (19, 20).  24 
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METHODS 1 
Study setting and design 2 
We conducted a prospective observational study of adults hospitalised with CAP at Queen 3 
Elizabeth Central Hospital - a 1200 bed teaching hospital that provides free healthcare to the 4 
1.3 million residents of Blantyre district in Southern Malawi. Ethical approval was provided 5 
by the Research Ethics Committees of University of Malawi College of Medicine 6 
(P.11/12/1309) and Liverpool School of Tropical Medicine (13.02). Some patients 7 
participated in linked case-control studies describing the impact of HIV on influenza severity 8 
(21) and the association of indoor air pollution exposure with pneumonia (22). 9 
Study procedures 10 
We recruited adults (≥18 years) hospitalised with clinically-diagnosed CAP defined as: 11 
reported or recorded fever (≥38°C); at least one relevant symptom (cough, chest pain, 12 
breathlessness, haemoptysis); and at least one focal chest sign (crepitations, pleural rub, 13 
bronchial breathing, percussive dullness or diminished breath sounds (adapted from (23)). 14 
Patients with symptoms for more than 14 days, current anti-tuberculous treatment or prior 15 
admission within the last month were excluded. Further details of the eligibility criteria are 16 
provided in the online data supplement. Written informed consent was provided by the 17 
patient, or in the case of incapacity, by their accompanying guardian.  18 
Patients underwent a standardised clinical assessment on admission, were reviewed daily 19 
during hospitalisation and then followed at 30-days and 90-days post admission to 20 
determine vital status. Blood, urine, sputum and nasopharyngeal aspirate (NPA) were 21 
collected at enrolment. Diagnostic pleural aspiration was performed in patients with 22 
radiologically confirmed pleural effusion. Clinical care was provided in accordance with local 23 
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guidelines and directed by the patients’ clinical team. 1 
Radiographic assessment  2 
Chest radiographs were performed as early as possible after admission and independently 3 
reported by two radiologists and a study clinician using a standardised form. A consensus 4 
report of the three assessors was used for analysis. Radiographic pneumonia was defined as 5 
the presence of consolidation or other parenchymal abnormality (including reticulonodular 6 
change, cavitation or miliary appearance) or pleural effusion (4). Additional details are 7 
provided in the online data supplement. 8 
Laboratory testing 9 
Haematological and biochemical analyses were performed by standard methods. HIV status 10 
was established by sequential rapid tests (Alere Determine™, Japan, and Uni-Gold™, Trinity 11 
Biotech, Ireland)(24) and CD4 cell count was performed on FACSCount¥ flow cytometer 12 
(Becton Dickinson, California, USA). Blood cultures were performed using aerobic bottles in 13 
the BacT/ALERT 3D automated system (bioMérieux, Marcy-L’Etoile, France) and isolates 14 
identified using standard procedures (25). Urine antigen testing was performed for the 15 
detection of Streptococcus pneumoniae (BinaxNOW; Alere, Massachusetts, USA) and, in a 16 
subset of patients, Legionella pneumophila (BinaxNOW; Alere, Massachusetts, USA). A PCR 17 
assay was performed on NPA specimens for the detection of: adenovirus; bocavirus; 18 
Chlamydia pneumoniae; coronaviruses 229E, HKU1, OC43 and NL63; enterovirus; human 19 
metapneumovirus; influenza A and B viruses; Mycoplasma pneumoniae; parainfluenza virus 20 
types 1 - 4; parechovirus; respiratory syncytial viruses and rhinovirus. Xpert MTB/RIF assay 21 
(Cepheid; California, USA) and mycobacterial microscopy and culture (BACTEC MGIT 960 22 
Mycobacterial Detection System; Becton Dickinson, Maryland, USA) were performed on 23 
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non-induced sputum specimens. When obtained, pleural fluid samples were sent for Gram-1 
stain, aerobic culture, mycobacterial microscopy and culture, and pneumococcal antigen 2 
testing. Further details of laboratory methods are provided in the online supplement. 3 
Statistical analysis 4 
Statistical analyses were performed with Stata version 12.1 (StataCorp; Texas, US). We 5 
tested for differences in continuous variables using Wilcoxon rank-sum test, and categorical 6 
variables by χ2 test or Fisher’s exact test as appropriate. Differences in microbial aetiology by 7 
radiographic status controlling for the effect of HIV were examined using the Mantel-8 
Haenszel method. 9 
Candidate risk factors for 30-day mortality were selected a priori based on literature review 10 
(26-29). Continuous variables, with the exception of age, were dichotomised at standard cut-11 
off points (29-32). Univariable analyses were performed using logistic regression to explore 12 
associations with 30-day mortality. Multivariable models were generated using age, sex, HIV 13 
status and all variables with a P values <0.2 on univariable analysis, prevalence of at least 5% 14 
and for which data were available in more than 95% of patients, and then rationalised by 15 
stepwise backwards elimination with removal of variables with a P value >0.05. The number 16 
of covariates in the multivariable model were limited to maintain at least 10 events per 17 
variable (33). Subgroup analyses of HIV-infected patients and those with radiographic 18 
pneumonia were performed. The association of aetiology with mortality was also assessed 19 
(see online supplement). All available case information was used in each univariable analysis. 20 
In multivariable models, we excluded patients with missing data for included variables.  21 
The prognostic performance of several CAP severity-assessment tools - CURB65 (29), CRB65 22 
(29), SMRT-CO (simplified version of the SMART-COP tool (34)), modified IDSA/ATS 2007 23 
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minor criteria (35) and SWAT-Bp (28) - for predicting 30-day mortality was described by 1 
calculating sensitivity, specificity, positive and negative predictive values, positive and 2 
negative likelihood ratios and area under the receiver-operating characteristic curve with 3 
95% confidence intervals (CI). Details of how scores were calculated for each severity-4 
assessment tool are provided in the online supplement (see Table 4). 5 
 6 
RESULTS 7 
Baseline characteristics 8 
Between 15th May 2013 and 31st January 2015 we screened 1711 adult patients, of whom 9 
489 fulfilled the eligibility criteria, 472 were enrolled and 459 included in the analysis (Figure 10 
1). The median age was 34.7 years (interquartile range (IQR): 29.4-41.9) and 285 (62.1%) 11 
were male (Table 1; see Table E1 in the Online Supplement). HIV infection was common 12 
(355/453; 78.4%; HIV status missing in 6 individuals) and often newly diagnosed (124/355; 13 
34.9%) whilst other comorbid illnesses were reported infrequently (31/451; 6.9%). 83.3% 14 
(189/227) of those known to be HIV-infected reported current ART use. Prior pneumonia 15 
was common (108/457; 23.6%) and associated with HIV (odds ratio (OR) 2.91; 95% CI: 1.46-16 
6.30). The median length of admission was 7 days (IQR: 4-10).  17 
Radiographic pneumonia was identified by consensus report in 317 (76.0%) of 417 patients 18 
with available interpretable chest radiographs with moderate inter-observer agreement 19 
(Kappa 0.75; 95% CI: 0.69-0.81; Table 1; see Table E2). Pleural effusion was identified in 20 
118/416 (28.4%), being the sole basis of defining radiographic pneumonia in 38/315 (12.1%). 21 
The proportion of patients with radiographic pneumonia did not vary with HIV status (HIV-22 
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infected 247/320 (77.2%) vs. HIV-uninfected 66/91 (72.5%); P=0.36) or with CD4 count (CD4 1 
<200 cells/mm3 176/222 (79.3%) vs. CD4 t 200 cells/mm3 49/64 (76.6%), P=0.64; CD4 count 2 
available in 315/355 (88.7%) HIV-infected patients). 3 
Aetiology 4 
Blood for aerobic culture was obtained from 450 of the 459 (98.0%) of the participants, NPA 5 
from 455/459 (99.1%) and urine specimen for Streptococcus pneumoniae antigen detection 6 
from 433/459 (94.3%) with stored specimens available for Legionella antigen testing in 193 7 
(see Table E5). At least one sputum specimen for a mycobacterial diagnostic test was 8 
obtained from 322/459 (70.2%) participants: smear microscopy, mycobacterial culture and 9 
Xpert MTB/RIF assay were completed in 305/459 (66.4%), 273/459 (59.5%) and 308/459 10 
(67.1%), respectively. A pleural fluid specimen was obtained in 35/459 (7.6%) patients: 11 
aerobic bacterial culture, Streptococcus pneumoniae antigen detection, mycobacterial smear 12 
microscopy and culture were completed in 31, 31 and 35 patients respectively.  13 
Overall at least one potential pathogen was identified in 278/459 (60.6%) patients including 14 
at least one bacteria in 125/452 (27.7%) and at least one virus in 148/459 (32.6%; Table 2). 15 
Streptococcus pneumoniae was the most commonly identified organism, present in 98 16 
(21.4%) of 458 for whom results of blood culture and/or urinary antigen assay were 17 
available, of whom 92 (93.9%) were identified by detection of urinary antigen alone (see 18 
Table E5). Pneumococcal aetiology was more common in HIV-uninfected patients (30/97 19 
(30.9%) vs. 68/355 (19.2%); P=0.01) and those with radiographic pneumonia (83/316 (26.3%) 20 
vs. 8/100 (8.0%); P<0.001; see Table E6), in particular confluent consolidation (OR 2.51; 95% 21 
CI: 1.26-4.98; see Table E7). Overall, 26 (5.8%) of 450 patients for whom blood was sent for 22 
culture were bacteraemic: Salmonella Typhi (n=9), nontyphoidal Salmonella (NTS; n=7) and 23 
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S. pneumoniae (n=5) were most commonly isolated. S. Typhi was identified more frequently 1 
in HIV-uninfected patients (5/94 (5%) vs. 3/350 (1%); P=0.02), whilst all cases of NTS 2 
infection occurred in HIV-infected patients, and both were more common amongst patients 3 
lacking radiographic pneumonia (see Table E6). Infection with Mycoplasma pneumoniae 4 
(6/455; 1.3%) and Chlamydia pneumoniae (2/455; 0.4%) were uncommon. None of the 193 5 
patients tested had a positive Legionella urinary antigen assay result. 6 
Overall, M. tuberculosis was identified in 75 (23.0%) of 326 patients who submitted a 7 
sputum and/or pleural fluid specimen (Table 2). TB was confirmed by culture in 65/75 8 
(86.7%) and diagnosed on the basis of Xpert MTB/RIF alone, sputum microscopy alone or 9 
pleural fluid microscopy alone in 8/75 (10.7%), 1/75 (1.3%) and 1/75 (1.3%) patients, 10 
respectively (see Table E5). Non-tuberculous mycobacteria were isolated in 8/273 (2.9%) for 11 
whom sputum for culture was obtained of whom 1 was smear positive. The frequency of TB 12 
did not differ significantly between the groups with and without radiographic pneumonia 13 
(58/232 (25%) vs. 13/68 (19.1%); see Table E6), although in the latter, TB displaced S. 14 
pneumoniae as the most commonly identified pathogen, with all cases occurring in HIV-15 
infected patients.  16 
Influenza (40/454; 8.8%), adenovirus (35/455; 7.7%) and coronavirus (31/455; 6.8%) were 17 
the most commonly detected viruses. Detection of these respiratory viruses was not 18 
associated with HIV status or the presence of radiographic pneumonia (see Tables 2 and E6). 19 
Co-infection relationships were investigated in 307 patients (66.9% of cohort) for whom 20 
results for blood culture, pneumococcal urine antigen, sputum mycobacterial culture and/or 21 
Xpert MTB/RIF, NPA PCR were available. At least one organism was detected in 206/307 22 
(67.1%) and co-infection with 2 or more organisms was present in 67/307 (21.8%; Figure 2); 23 
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the combination of bacterial-viral co-infection was most frequent (28/307; 9.1%). S. 1 
pneumoniae was co-detected in one-fifth of patients with influenza (6/31; 19.4%). M. 2 
tuberculosis was isolated in 9.6% (7/73) of those with S. pneumoniae (see Table E8). 3 
Detection of multiple organisms did not vary with HIV status (54/243 (22.2%) vs. 12/62 4 
(19.4%)). 5 
Mortality 6 
439 of 459 (95.6%) patients were successfully followed to 30 days of whom 64 (14.6%) had 7 
died, including 15 and 31 within the first 3 and 7 days following admission, respectively 8 
(Table 1). 418 were followed to 90 days of whom an additional 23 had died. Male sex (aOR 9 
2.60; 95% CI: 1.17-5.78), pre-presentation symptom duration >7 days (aOR 2.78; 95% CI: 10 
1.40-5.54), heart rate ≥125 per minute (aOR 2.99; 95% CI: 1.48-6.06), oxygen saturations 11 
<90% (aOR 4.40; 95% CI: 2.03-9.51) and inability to stand (aOR 3.59; 95% CI: 1.72-7.50) were 12 
independently associated with 30-day mortality (Table 3). Neither age nor any underlying 13 
comorbid illness, including HIV, or initial antimicrobial treatment was found to be 14 
significantly associated with 30-day mortality. Detection of S. pneumoniae was associated 15 
with reduced mortality (aOR 0.40; 95% CI: 0.17-0.91; see Table E9), whilst TB was associated 16 
with increased mortality (aOR 2.44; 95% CI: 1.19-5.01). Mortality did not vary with detection 17 
of multiple organisms compared to a single organism (5/65 (7.7%) vs. 13/135 (9.6%); 18 
P=0.80).  19 
In a subgroup analysis of the 342 HIV-infected patients followed to day 30, symptom 20 
duration >7 days (aOR 3.56; 95% CI: 1.60-7.93), heart rate ≥125 per minute (aOR 3.06; 95% 21 
CI: 1.40-6.71), oxygen saturations <90% (aOR 2.97; 95% CI: 1.28-6.88), inability to stand (aOR 22 
4.25; 95% CI: 1.84-9.79) and CD4 count <50 cells/mm3 (aOR 2.30; 95% CI: 1.07-4.92) were 23 
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associated with mortality in multivariable analysis (see Table E10). CD4 count <200 1 
cells/mm3 was not associated with mortality (OR 1.63; 95% CI: 0.69-3.83). In the subgroup of 2 
305 patients with radiographic pneumonia followed to day 30, symptom duration >7 days 3 
(aOR 3.30; 95% CI: 1.37-7.96), heart rate ≥125 per minute (aOR 2.66; 95% CI: 1.08-6.57) and 4 
multilobar consolidation (aOR 2.75; 95% CI: 1.17-6.47) were significantly associated with 5 
mortality, with a trend towards an association for inability to stand (aOR 2.63; 95% CI: 1.00-6 
6.89; see Table E11). 30-day mortality was however significantly higher in the small group of 7 
patients for whom a chest radiograph was unavailable (17/36 (47.2%) vs. 47/403 (11.7%); 8 
P<0.0001; see Table E3).  9 
Prognostic performance of severity-assessment tools 10 
Of the CAP severity-assessment tools examined, SMRT-CO had the highest sensitivity (89.7%; 11 
95% CI: 72.6-97.8), negative predictive value (96.8%; CI: 91.0-99.3%) and overall 12 
discriminatory capability (AUROC 0.66; 95% CI: 0.57-0.75) for 30-day mortality (Table 4). 13 
CURB65 had poor sensitivity and discriminatory capability. Only 38 (8.8%) patients had 14 
‘severe CAP’ by CURB65 (i.e. score ≥3) and mortality amongst those with ‘mild CAP’ (i.e. 15 
CURB65 ≤1) was 10.8% (29/268). The prognostic performance of each tool was similarly poor 16 
in the subgroup with radiographic pneumonia (see Table E12). 17 
 18 
DISCUSSION  19 
In this prospective study of acute CAP in adults that is amongst the largest conducted in sub-20 
Saharan Africa, we have shown that: the burden of hospitalised pneumonia in adults 21 
predominantly remains in young, HIV-infected patients; tuberculosis and vaccine-22 
preventable pathogens such as S. pneumoniae and influenza are common; mortality is 23 
CAP in Malawian adults 
12 
substantial and associated with potentially modifiable risk factors but poorly predicted by 1 
widely-used CAP severity-assessment tools.  2 
Although completed within the era of ART scale-up, 35% of HIV-infected patients were 3 
newly diagnosed, 17% of those with known HIV were not receiving ART and more than 4 
three-quarters had advanced immunosuppression (i.e. CD4 <200 cells/mm3). Further 5 
substantial reductions in CAP incidence may therefore be achieved by improved HIV testing 6 
and linkage to early initiation of ART (36).  7 
At first glance, the overall crude mortality rate of 14.6% is comparable to that seen in well-8 
resourced settings (26, 29, 37). However, a recent UK cohort reported 30-day mortality of 9 
1.5% in patients under 50 (38), suggesting a substantially higher age-adjusted mortality rate 10 
in our cohort. The identified associations of TB and uncorrected hypoxaemia with death, 11 
may explain some of this apparent large discrepancy in mortality rate. In keeping with other 12 
studies of acute CAP (7, 27, 28), we did not find evidence that HIV overall influenced 13 
outcome; increased mortality was evident in only the most profoundly 14 
immunocompromised with CD4 cell count <50 cells/mL.  15 
Given the observed strong association of hypoxaemia with mortality, expansion of 16 
supplemental oxygen provision, which across much of sub-Saharan Africa is currently 17 
severely limited (39), represents an obvious strategy to be evaluated in an effort to improve 18 
CAP outcomes. Programmatic interventions in children in low-resource settings based on 19 
improved oxygen supply using oxygen concentrators have been associated with a 35% 20 
reduction in mortality (40). The lack of association between respiratory rate and mortality 21 
underlines the importance of expanding the availability of pulse oximetry in tandem. 22 
Similarly, the association of pre-presentation symptom duration with mortality suggests that 23 
CAP in Malawian adults 
13 
interventions to improve patient education to alter healthcare-seeking behaviour or referral 1 
mechanisms within community healthcare centres should be considered. The continued 2 
substantial mortality rate beyond day 30 also warrants further study to devise targeted 3 
interventions to enhance care following discharge from hospital.  4 
The use of objective CAP severity assessment tools has been shown to improve both the 5 
recognition of patients with severe CAP likely to require intensive care support (41) and 6 
those with mild disease who can be safely managed as outpatients (42). Current South 7 
African CAP guidelines recommend that CURB65 is used to inform site of care and initial 8 
antimicrobial treatment (43). However, we found that CURB65 showed poor prognostic 9 
performance in predicting 30-day mortality in this cohort compared to its performance in 10 
CAP cohorts from well-resourced settings (44). This variation likely reflects differences in 11 
microbial aetiology, demographics and comorbidity profiles between this cohort and the 12 
patient populations in which CURB65 was derived (29, 37), and underlines the importance of 13 
prospective validation of prognostic tools in relevant settings (29, 44). The similarly poor 14 
performance of the SWAT-Bp score that was derived in a LRTI cohort from Malawi (28), 15 
however, highlights the challenges of developing a simple and accurate locally-adapted tool. 16 
Rather than attempting to derive a single tool capable of accurately predicting mortality 17 
across the whole spectrum of disease severity, a tool with high negative predictive 18 
performance aimed at identifying those patients with a low risk of adverse outcome suitable 19 
for outpatient management may be more feasible and equally useful. In this respect, the 20 
SMRT-CO tool performed well with a negative predictive value of 96.8%, but the inclusion of 21 
a radiographic parameter (i.e. multilobar involvement (34)) limits its use as a triage tool in 22 
settings where chest radiography might not be readily available. 23 
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Recent CAP studies corroborate our observation that S. pneumoniae remains the 1 
commonest identified cause of adult CAP in sub-Saharan Africa (6, 10, 27). Universal infant 2 
vaccination with PCV was introduced in Malawi in 2011, approximately 2.5 years before the 3 
start of recruitment. Following the introduction of PCV in the US and South Africa, rates of 4 
adult pneumococcal disease – including pneumonia hospitalisations – fell rapidly as a result 5 
of indirect protection due to reduced pneumococcal transmission from vaccine recipients 6 
(45, 46). Further studies are needed to describe the serotype distribution of pneumococcal 7 
pneumonia in Malawi, to determine whether targeted vaccination programmes of at risk 8 
groups may be beneficial to tackle the persistent burden of adult disease. Recently 9 
developed urinary assays that can detect serotype-specific antigens in non-invasive 10 
pneumococcal pneumonia may provide a more comprehensive description (47).  11 
When adequate diagnostic tests are performed, TB is identified in a substantial proportion of 12 
patients presenting with acute CAP in sub-Saharan Africa with the major burden of disease 13 
and associated mortality occurring in HIV-infected individuals (7-9, 27). At 23% of those 14 
tested and 16% of the overall cohort, the frequency of TB is similar to that previously 15 
reported (7-9, 27), but probably underestimates the true burden given the reliance on 16 
spontaneously expectorated sputum specimens and a single specimen submitted for culture. 17 
In most sub-Saharan African settings, laboratory diagnosis of TB has until recently relied on 18 
sputum smear microscopy that has poor sensitivity, particularly for HIV-associated TB. The 19 
WHO has advocated an empirical “step-up” approach, whereby anti-tuberculous treatment 20 
is initiated for HIV-infected adults with features of severe respiratory infection and negative 21 
sputum smears who fail to improve after 3-5 days of antibacterial treatment (48). Whilst this 22 
approach may limit inappropriate anti-tuberculous treatment, it may miss up to 20% of 23 
patients with culture positive TB and risks delaying treatment in a group of patients with a 24 
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very high risk of early death (49). The increasingly available Xpert MTB/RIF assay used in this 1 
study offers much improved sensitivity and is now recommended as the first-line diagnostic 2 
for HIV-associated TB (50). Rapid urine-based diagnostics (e.g. urine Xpert MTB/RIF, 3 
mycobacterial glycopeptide lipoarabinomannan assay) may have a complementary role to 4 
guide initiation of anti-tuberculous treatment, particularly for acutely ill patients from whom 5 
sputum is frequently unobtainable (51, 52). 6 
In keeping with recent CAP studies from well-resourced settings that have utilised molecular 7 
diagnostics (4, 53), we identified high rates of co-infection with multiple organisms, most 8 
commonly bacterial-viral co-isolation. Defining the clinical significance of each organism 9 
detected is challenging, particularly amongst immunocompromised individuals. Whilst co-10 
isolation may reflect genuine co-pathogenicity or simply detection of bystander colonising 11 
organisms, more complex relationships in which one organism facilitates the acquisition or 12 
pathogenesis of another (e.g. influenza and S. pneumoniae (54)) are possible. Bacterial-viral 13 
coinfection has been associated with altered levels of innate immune factors (e.g. CRP, IP10 14 
(55)) and more severe clinical course (56). Further work is needed to define the implications 15 
for CAP therapy and prevention.  16 
Radiographic facilities are limited in most healthcare facilities in sub-Saharan Africa where 17 
the majority of CAP patients are initially managed. Whilst the clinical case definition used in 18 
this study may have missed some patients with radiographic pneumonia who lacked focal 19 
signs at the time of recruitment it nonetheless reflects routine clinical practice and usefully 20 
provides data to show how the aetiological spectrum of disease varies with chest radiograph 21 
findings (57). The association of radiographic changes compatible with infection with S. 22 
pneumoniae is unsurprising. Although still relatively uncommon, the greater prevalence of 23 
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invasive Salmonella infection amongst those lacking radiographic pneumonia has important 1 
implications for antimicrobial management. Whilst specific radiological features were 2 
statistically associated with certain pathogens, the marked inter-observer variability in 3 
interpretation of these features suggests that the clinical utility of this approach is limited.  4 
In recruiting patients exclusively from a single referral hospital, this study shares the 5 
limitations common to many CAP observational cohorts. Most patients were seen at another 6 
facility prior to attendance; how they were selected for referral and correspondingly, the 7 
characteristics and outcome of those treated at home is unknown. Hence, the applicability 8 
of the findings to community level settings is potentially limited. Extrapolation of these 9 
findings to other countries in sub-Saharan Africa must also be done cautiously because of 10 
the potential impact that variations in factors such as TB incidence, HIV-prevalence and 11 
climate may have on CAP epidemiology and aetiology. Given limitations of the healthcare 12 
infrastructure in Malawi, chronic comorbid illnesses may be underdiagnosed. Inconsistencies 13 
in drug supply, equipment provision and staff experience may result in variations in CAP 14 
treatment that may impact patient outcome but are not fully accounted for in analyses. The 15 
description of CAP aetiology was limited by the lack of sputum microscopy and culture which 16 
may have increased the detection of bacterial pathogens such as Haemophilus influenzae as 17 
has been described in previous studies from the region (27, 58). Similarly, we were unable to 18 
support invasive respiratory sampling for diagnostic testing for Pneumocystis jirovecii (PCP) 19 
and other HIV-associated opportunistic pathogens. The low rate of bacteraemia observed 20 
may relate to both pre-hospital antibiotic use and antibiotic initiation prior to blood couture 21 
collection in hospital which occurred in up to one-third of patients. Interpretation of the 22 
significance of respiratory pathogen multiplex PCR results, particularly for respiratory 23 
viruses, is hampered by the lack of data from an appropriate control population. The relative 24 
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contribution of pathogens with seasonal transmission patterns (e.g. influenza) may also have 1 
been skewed by a recruitment period that spanned two incomplete years. 2 
In conclusion, more than a decade after the introduction of ART, the major burden of CAP in 3 
Malawi remains in young, HIV patients rather than the elderly patients with chronic non-4 
communicable comorbidities that predominate in well-resourced settings. Accordingly, 5 
context-specific approaches to severity assessment and defining empirical antimicrobial 6 
treatment are needed. The predominance of S. pneumoniae and influenza suggest significant 7 
opportunities for CAP prevention through targeted vaccination programmes. Strategies to 8 
encourage prompt patient presentation, to increase early detection and treatment of TB and 9 
to improve supportive care, in particular the correction of hypoxaemia, should be evaluated 10 
in clinical trials to address the high burden of CAP-related mortality.   11 
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Figure 1. Recruitment and follow-up of a cohort of Malawian adults hospitalised 1 
community-acquired pneumonia. *Some patients excluded for multiple reasons hence totals 2 
exceed total number excluded.  3 
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Figure 2. Bacterial, viral and mycobacterial infection in isolation and combination in 1 
Malawian adults hospitalised with community-acquired pneumonia. Aetiology defined by 2 
blood culture, Streptococcus pneumoniae urinary antigen detection, sputum mycobacterial 3 
culture and Xpert MTB/RIF, and nasopharyngeal aspirate respiratory pathogen multiplex 4 
PCR. Analysis restricted to 307 patients with results available for all tests. 5 
  6 
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Table 1. Demographic, clinical and radiographic characteristics of 459 Malawian adults 1 
hospitalised with community-acquired pneumonia. 2 
Characteristic No. (%) of episodes 
Demographics   
Male sex 285/459 (62.1) 
Age* 34.7 (29.4-41.9) 
HIV status   
HIV positive† 
Newly diagnosed 
355/453 
124/355 
(78.4) 
(34.9) 
CD4 cell count (cells/mm3)† 
All HIV-positive 
Newly diagnosed HIV-positive 
 
99 
93 
 
(44-193) 
(43-179) 
ART use in known HIV-positive† 189/227 (83.3) 
Medical history   
Any other comorbid condition 31/451 (6.9) 
Chronic lung disease‡ 15/452 (3.3) 
Chronic heart disease§ 3/452 (0.7) 
Hypertension 8/452 (1.8) 
Previous tuberculosisll 84/458 (18.3) 
Previous pneumonia in last 5 years** 108/457 (23.6) 
Pregnancy 2/174 (1.2) 
Current smoker 50/457 (10.9) 
Pre-hospital/clinic attendance & treatment   
Attended another health facility†† 283/458 (61.8) 
Antibiotics within 2 weeks‡‡ 280/455 (61.5) 
Antimalarials within 2 weeks 79/457 (17.3) 
Traditional remedies within 2 weeks 40/456 (8.8) 
Baseline observations   
Temperature (°C)* 
<35 or ≥40 
37.9 
14/459 
(37.1-38.9) 
(3.1) 
Systolic BP (mmHg)* 
<90 
106 
86/454 
(93-121) 
(18.9) 
Diastolic BP (mmHg)* 
≤60 
68 
143/454 
(59-78) 
(31.5) 
Heart rate (beats/min)* 
≥125 
118 
176/458 
(102-132) 
(38.4) 
Respiratory rate (breaths/min)* 
≥30  
29 
213/446 
(26-34) 
(47.8) 
Oxygen saturations (%)* 
<90 
95 
73/450 
(91-98) 
 (16.2) 
Body mass index (kg/m2)* 
<18.5 
19.9 
132/444 
(18.2-21.8) 
(29.7) 
  3 
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Characteristic No. (%) of episodes 
Baseline laboratory results   
Haemoglobin (g/dL)* 
<8 
11 
74/449 
(9.0-12.8) 
(16.5) 
White blood cells (x 109 cells/L)* 
<4 
≥15 
7.7 
67/448 
x63/448 
(5.0-11.4) 
(15.0) 
(14.1) 
Urea (mmol/L)* 
>7 
4.8 
137/450 
(3.3-8.0) 
(30.4) 
Creatinine (μmol/L)* 
>120 
76 
76/448 
(59-100) 
(17.0) 
Radiological features§§   
Radiographic pneumonia 317/417 (76.0) 
Consolidation 251/313 (80.2) 
Multilobar involvement 73/247 (29.6) 
Cavitation 20/317 (6.3) 
Pleural effusion 118/315 (37.5) 
Outcomellll   
Inpatient mortality 51/457 (11.2) 
Day 30 mortality 64/439 (14.6) 
Day 90 mortality 87/418 (20.8) 
Definition of abbreviations: ART = antiretroviral therapy; BP = blood pressure; IQR = 
interquartile range 
Data are n/N (%)unless indicated by * where median and interquartile range are 
shown. Variation in denominator reflecting missing data unless further specified. 
†HIV status missing in 6 patients; CD4 count missing in 40 of all with HIV; ART usage 
missing in 4 with known HIV. 
‡Chronic lung disease includes asthma, COPD and bronchiectasis.  
§Chronic heart disease includes congestive cardiac failure, cor pulmonale and dilated 
cardiomyopathy.  
llAny previous episode of treated tuberculosis regardless of site and confirmation.  
**Any prior episode within the last 5 years of a syndrome compatible with lower 
respiratory tract infection reviewed in a healthcare facility and treated with 
antibiotics.  
††Included attendance to other hospital, health centre, private clinic, traditional 
healer or pharmacy.  
‡‡Excluded co-trimoxazole prophylaxis in HIV-infected individuals. 
§§Chest radiographs available in 421 patients; reports based on consensus grading of 
assessors and denominator may vary when consensus not obtained.   
llllStatus at hospital discharge, day 30 and day 90 missing in 2, 20 and 41, respectively. 
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Table 2. Aetiology of community-acquired pneumonia in Malawian adults stratified by HIV status. 1 
Organism All
* 
(n=459) 
      HIV-positive 
        (n=355) 
HIV-negative 
(n=98) P for difference
† 
Streptococcus pneumoniae 98/458 (21.4) 68/355 (19.2) 30/97 (30.9) 0.01 
Salmonella Typhi 10/450 (2.2) 4/350 (1.1) 5/94 (5.3) 0.02‡ 
Nontyphoidal Salmonella§ 7/450 (1.6) 7/350 (2) 0/94 (0) 0.35‡ 
Other GNEBll 3/450 (0.7) 3/350 (0.9) 0/94 (0) 1.00‡ 
Staphylococcus aureus 2/450 (0.4) 1/350 (0.3) 1/94 (1.1) 0.38‡ 
Mycoplasma pneumoniae 6/455 (1.3) 6/355 (1.7) 0/98 (0) 0.35‡ 
Chlamydia pneumoniae 2/455 (0.4) 0/355 (0) 2/98 (2.0) 0.05‡ 
Legionella pneumophila 0/193 (0) 0/154 (0) 0/38 (0) - 
Mycobacterium tuberculosis 75/326 (23.0) 64/257 (24.9) 10/64 (15.6) 0.12 
Nontuberculous mycobacteria 8/273 (2.9) 5/217 (2.3) 3/52 (5.8) 0.19‡ 
Influenza viruses 40/454 (8.8) 30/354 (8.5) 9/98 (9.2) 0.83 
Adenovirus 35/455 (7.7) 30/355 (8.5) 5/98 (5.1) 0.39‡ 
Coronaviruses 31/455 (6.8) 28/355 (7.9) 3/98 (3.1) 0.11‡ 
Parainfluenza viruses 17/455 (3.7) 15/355 (4.2) 1/98 (1) 0.21‡ 
Rhinovirus 17/455 (3.7) 15/355 (4.2) 2/98 (2) 0.55‡ 
Bocavirus 13/455 (2.9) 13/355 (3.6) 0/98 (0) 0.08‡ 
Metapneumovirus 9/455 (2.0) 8/355 (2.3) 1/98 (1) 0.69‡ 
RSV 8/455 (1.8) 4/355 (1.1) 3/98 (3.1) 0.18‡ 
Enterovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 0.59‡ 
Parechovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 0.59‡ 
No pathogen detected 181/459 (39.4) 137/355 (38.6) 42/98 (42.9) 0.44 
Definition of abbreviations: GNEB = Gram-negative enteric bacilli; OR = odds ratio; RSV = respiratory syncytial virus. 
Data are n/N (%). Denominators indicate number of patients with at least one relevant test available. S. pneumoniae 
diagnosis based on combination of blood and pleural fluid culture and antigen assay of urine and pleural fluid. M. 
tuberculosis based on combination of sputum microscopy, culture and Xpert MTB/RIF and pleural fluid culture. Other 
organisms based on single test. Column totals exceed number of patients since multiple organisms detected in some. 
*Includes 6 patients with missing HIV status in whom the following organisms were identified: Salmonella Typhi, 1; 
Mycobacterium tuberculosis, 1; Influenza, 1; Parainfluenza, 1; RSV, 1; No pathogen detected, 2. 
†χ2 test unless otherwise stated.  
‡Fisher’s exact test.  
§S. Enteritidis and S. Typhimurium combined. 
llEscherichia coli and Enterobacter cloacae combined. 
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Table 3. Association of candidate clinical and laboratory risk factors with 30-day mortality 1 
in Malawian adults hospitalised with community-acquired pneumonia. 2 
Characteristic Day 30 survivors (n=375) 
Day 30 
mortality 
(n=64) 
Univariable analysis Multivariable analysis 
OR (95% CI) P aOR (95% CI) P 
Male sex 224/375 (59.7) 52/64 (81.3) 2.92 (1.51-5.66) 0.001 2.60 (1.17-5.78) 0.02 
Age (yrs) 34 (29-42) 36 (32-42) 1.00 (0.98-1.03) 0.73 1.00 (0.97-1.03) 0.93 
Current smoker 41/373 (11.0) 7/64 (10.9) 0.99 (0.43-2.33) 0.99 - - 
Regular alcohol use 92/373 (24.7) 23/63 (36.5) 1.76 (1.00-3.09) 0.05 - - 
Unemployed 109/357 (30.5) 13/61 (21.3) 0.62 (0.32-1.18) 0.15 - - 
HIV-positive 288/370 (77.8) 54/64 (84.4) 1.53 (0.75-3.15) 0.24 1.26 (0.49-3.21) 0.63 
Chronic lung disease 11/371 (3.0) 3/61 (4.9) 1.69 (0.46-6.23) 0.43 -* - 
Chronic heart disease 2/370 (0.5) 1/61 (1.6) 3.07 (0.27-34.35) 0.36 -* - 
Renal disease 0/371 (0) 1/61 (1.6) - - -* - 
Pre-presentation 
symptoms >7 days 
138/374 (36.9) 36/63 (57.1) 2.28 (1.33-3.92) 0.003 2.78 (1.40-5.54) 0.004 
Travel time ≥1 hour 278/373 (74.5) 51/62 (82.3) 1.58 (0.79-3.16) 0.19 - - 
Previous review 231/375 (61.6) 42/63 (66.7) 1.25 (0.71-2.19) 0.44 - - 
Temperature <35 or ≥40 °C 13/375 (3.5) 1/64 (1.6) 0.44 (0.06-3.44) 0.44 -* - 
Systolic BP <90 mmHg 66/371 (17.8) 17/63 (27.0) 1.71 (0.92-3.16) 0.09 - - 
Diastolic BP ≤60 mmHg 112/371 (30.2) 28/63 (44.4) 1.85 (1.07-3.19) 0.03 -‡ - 
Mean arterial BP <65 
mmHg 
46/371 (12.4) 15/63 (23.8) 2.21 (1.14-4.26) 0.02 -‡ - 
Heart rate ≥125 /min 135/374 (36.1) 37/64 (57.8) 2.43 (1.42-4.16) 0.001 2.99 (1.48-6.06) 0.002 
Resp. rate≥30 /min) 172/364 (47.3) 33/62 (53.2) 1.27 (0.74-2.18) 0.39 - - 
Oxygen satn <90 % 45/368 (12.2) 27/63 (42.9) 5.38 (2.99-9.70) <0.0001 4.40 (2.03-9.51) <0.001 
BMI <18.5 kg/m2 108/366 (29.5) 20/61 (32.8) 1.17 (0.65-2.08) 0.61 -§ - 
MUAC <230 mm 103/371 (27.8) 14/63 (22.2) 0.74 (0.39-1.40) 0.36 - - 
Confusion 2/374 (0.5) 3/64 (4.7) 9.15 (1.50-55.87) 0.02 -* - 
Inability to stand 57/375 (15.2) 30/64 (46.9) 4.92 (2.79-8.67) <0.0001 3.59 (1.72-7.50) 0.001 
Haemoglobin <8 g/dL 55/368 (15.0) 18/61 (29.5) 2.38 (1.28-4.43) 0.006 - - 
White cell count <4 x 109/L 50/367 (13.6) 15/61 (24.6) 2.07 (1.07-3.98) 0.03 - - 
Platelets <100 x 109/L 58/368 (15.8) 14/61 (23.0) 1.59 (0.82-3.08) 0.17 - - 
Urea >7 mmol/L 107/370 (28.9) 27/60 (45.0) 2.01 (1.15-3.51) 0.01 - - 
Creatinine >120 μmol/L 56/369 (15.2) 15/59 (25.4) 1.91 (0.99-3.65) 0.05 - ll  - 
Glucose ≥14 mmol/L 0/330 (0) 0/53 (0) - - -† - 
Definition of abbreviations: BP = blood pressure; BMI = body mass index; CI = confidence interval; MUAC = mid-upper arm 
circumference; OR = odds ratio; Resp. = respiratory 
For age (in italics) data shown as median and interquartile range. Otherwise data shown as n/N (%) with variation in 
denominator compared to column header reflecting missing data. Univariable and multivariable analyses by logistic 
regression. For age, odds ratio indicates change in risk of mortality with each year increase. 20 patients of overall study 
cohort of 459 excluded due to unknown 30-day outcome. Final multivariable analysis based on 380 patients with complete 
results for all included parameters.   
*Excluded from multivariable analysis because of prevalence ≤5%.  
†Excluded from multivariable analysis because data were missing for >5% of patients. 
‡Excluded a priori from multivariable analysis because of assumed collinearity with systolic blood pressure.  
§Excluded a priori because of assumed collinearity with MUAC.  
llExcluded a priori because of assumed collinearity with urea.  
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Table 4. Accuracy of pneum
onia severity-assessm
ent tools for predicting 30-day m
ortality in a cohort of M
alaw
ian adults hospitalised w
ith 
1 
com
m
unity-acquired pneum
onia cohort. 
2 
Score group 
n
* 
Sensitivity %
  
(95%
 CI) 
Specificity %
 
(95%
 CI) 
PPV %
 
(95%
 CI) 
NPV %
 
(95%
 CI) 
Positive LR 
(95%
 CI) 
Negative LR 
(95%
 CI) 
AUROC 
(95%
 CI) 
CURB65 ≥3 
412 
14.0 (6.3-25.8) 
91.5 (88.2-94.2) 
21.1 (9.6-37.3) 
86.9 (83.1-90.1) 
1.66 (0.80-3.44) 
0.94 (0.84-1.05 
0.60 (0.52-0.67) 
CRB65 ≥2 
421 
27.9 (17.1-40.8) 
81.9 (77.6-85.8) 
20.7 (12.6-31.1) 
87.0 (83.0-90.4) 
1.54 (0.97-2.44) 
0.88 (0.75-1.04) 
0.57 (0.50-0.65) 
SM
RT-CO ≥2 
280 
89.7 (72.6-97.8) 
36.7 (30.7-42.9) 
14.1 (9.4-19.9) 
96.8 (91.0-99.3) 
1.42 (1.21-1.65) 
0.28 (0.10-0.83) 
0.66 (0.57-0.75) 
M
odified IDSA/ATS 
m
inor criteria ≥3 
272 
48.3 (29.4-67.5) 
72.0 (65.9-77.6) 
17.1 (9.7-27.0) 
92.1 (87.3-95.5) 
1.73 (1.13-2.64) 
0.72 (0.50-1.03) 
0.66 (0.56-0.75) 
SW
AT-Bp ≥3 
427 
54.1 (40.8-66.9) 
68.3 (63.3-73.0) 
22.1 (15.8-29.7) 
89.9 (85.8-93.2) 
1.71 (1.30-2.25) 
0.67 (0.51-0.89) 
0.65 (0.57-0.72) 
Definition of abbreviations: AUROC = area under receiver-operating characteristic curve; CI = confidence interval; CURB65 = tool based on presence of confusion, urea >7m
m
ol/L, respiratory rate 
≥30/m
in, systolic blood pressure <90m
m
Hg and/or diastolic blood pressure ≤60m
m
Hg, age ≥65 (29); CRB65 = as per CURB65 w
ith exclusion of urea (29); IDSA/ATS = m
odified version of 
Infectious Disease Society of Am
erica/Am
erican Thoracic Society criteria based on presence of respiratory rate t30/m
in, oxygen saturations d90%
 (used as a surrogate for arterial oxygen 
pressure/fraction of inspired oxygen (PaO
2 /FiO
2 ) ratio d250 criterion included in the published tool), m
ultilobar infiltrates, confusion/disorientation, urea t7.1 m
m
ol/L, w
hite blood cell count <4 
x10
9 cells/L, platelets <100 x10
9 cells/L, tem
perature <36qC, systolic blood pressure < 90 m
m
Hg (used as a surrogate for hypotension requiring aggressive fluid resuscitation; (35); LR = likelihood 
ratio; NPV = negative predictive value; PPV = positive predictive value; SM
RT-CO = tool based on presence of systolic blood pressure < 90 m
m
Hg, m
ultilobar consolidation, respiratory rate 
t25/m
in if d50 years or t30/m
in if >50 years, heart rate t125/m
in, confusion and oxygen saturations d93%
 if d50 yrs or d90%
 if >50 yrs (34); SW
AT-Bp = tool based on m
ale sex, w
asting, non-
am
bulatory status, tem
perature <35qC or >38qC and systolic blood pressure <100 m
m
Hg or diastolic blood pressure <60 m
m
Hg (28). For each tool, the perform
ance characteristics displayed are 
those using the scoring threshold for “severe CA
P” as suggested by the authors. *Score calculated in varying num
ber of patients depending on availability of results for com
ponent param
eters; 
SM
RT-CO &
 m
odified IDSA/ATS m
inor criteria include radiological param
eter hence only calculated in those w
ith radiographic pneum
onia. 
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SUPPLEMENTARY METHODS 1 
Study design and conduct 2 
We conducted a prospective observational study of adults hospitalised with CAP at 3 
Queen Elizabeth Central Hospital (QECH) - a 1200 bed teaching hospital that provides free 4 
healthcare to the 1.3 million residents of Blantyre district in Southern Malawi. 5 
Recruitment commenced on 15th May 2013 and continued until 31st January 2015. 6 
Participant follow-up was completed by 28th May 2015.  7 
Detailed inclusion and exclusion criteria 8 
Clinical aspects of the study were completed by a dedicated team of research nurses and 9 
clinical officers who had received extensive training prior to study initiation. Study 10 
investigators (SA, AH, HJ, JH and TM) accompanied the clinical study team on their daily 11 
rounds at least weekly to evaluate data quality and consistency of data collection. 12 
Patients with features of respiratory illness or infection were screened on arrival in the 13 
hospital emergency department or on the medical wards within 24 hours of admission. 14 
Consenting adults with clinically diagnosed community-acquired pneumonia (CAP) as 15 
defined by the eligibility criteria below (summarised in the Methods section) were 16 
recruited. 17 
Inclusion criteria 18 
We recruited adults (≥18 years) hospitalised with clinically-diagnosed CAP defined as: 19 
reported or recorded fever (≥38°C); at least one relevant symptom (cough, chest pain, 20 
breathlessness, haemoptysis); and at least one focal chest sign (crepitations, pleural rub, 21 
bronchial breathing, percussive dullness or diminished breath sounds) (E1). 22 
 23 
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Exclusion criteria 1 
Patients with any of the following were excluded from participation: symptoms for 2 
greater than 14 days; suspected co-existent meningitis; pre-admission diagnosis of 3 
terminal illness (e.g. metastatic malignancy, terminal AIDS); current anti-tuberculous 4 
treatment; admission to hospital more than 24 hours previously; prior hospitalisation 5 
within preceding 4 weeks; or prior participation in the study. 6 
Clinical assessment and follow-up 7 
For each participant, the study team completed a standardised clinical assessment 8 
consisting of a comprehensive medical history, physical examination and measurement of 9 
physiological observations. Information was obtained via direct questioning of the study 10 
participant (or accompanying guardian) and by reference to medical notes and health 11 
passport. Physiological observations were measured by the study team on admission or 12 
abstracted from the medical notes for patients recruited from the medical wards. In lieu 13 
of a validated cognitive assessment tool that is not available in Malawi, the presence of 14 
confusion was determined using three standardised questions assessing orientation in 15 
time, place and person.  16 
Study participants were reviewed on a daily basis each morning until discharge or 14 days 17 
post-admission. At the point of hospital discharge or inpatient death, the study team 18 
reviewed the clinical notes and recorded details of treatment administered. Patients 19 
surviving to discharge were contacted at 30-days and 90-days post admission to 20 
determine vital status and hospital readmission. Two attempts were made to obtain this 21 
information by phone call to the patient or their guardian; if unsuccessful field workers 22 
visited the patient’s home. 23 
Patients with influenza formed the case population of a linked case-control study 24 
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 4 
describing the impact of HIV on influenza severity (E2). Some patients with radiographic 1 
pneumonia who survived to discharge also participated in a further case-control study of 2 
the association of exposure to indoor air pollution with the occurrence of pneumonia 3 
(E3). 4 
Radiographic assessment 5 
During the period of the study, there was no functional portable radiograph machine 6 
available at QECH; consequently, radiographs were not performed in clinically unstable 7 
patients that could not be safely transferred to the radiology department. Plain chest 8 
radiograph films were photographed on a light-box using a standard light-reflex digital 9 
camera mounted on a tripod in a darkened room. All study radiograph reports were 10 
generated by review of the set of digital images.  11 
Chest radiographs were reported independently by two study radiologists (EJ and SG) and 12 
the study Principal Investigator (SA, an Infectious Diseases Resident Physician). All 13 
reporters were blinded to demographic and clinical data at the time of reporting. 14 
Radiographs were reported using a standardised form, that was piloted prior to use for 15 
study reporting to ensure consistent application. Definitions of radiological features were 16 
based on the Fleischner Society: Glossary of terms for thoracic imaging (E4).  17 
Parenchymal abnormalities were categorised as consolidation, reticulonodular change, 18 
miliary appearance and cavitation. Consolidation was further characterised in terms of its 19 
quality (confluent or patchy), extent (segmental, lobar or multifocal) and distribution 20 
(lower, mid- and/or upper zone, or diffuse). Radiographic pneumonia was defined as the 21 
presence of consolidation or other parenchymal abnormality (including reticulonodular 22 
change, cavitation or miliary appearance) or pleural effusion (E5). Multilobar 23 
consolidation was not specifically reported on the form; consolidation was considered to 24 
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be multilobar if characterised as diffuse, present in two or more non-contiguous lung 1 
zones regardless of extent or present in two or more contiguous lung zones and 2 
characterised as multifocal. Multifocal consolidation within a single lung zone was not 3 
classified as multilobar. Study analyses were based on a consensus report for each 4 
specific feature. If there was disagreement between the reporters, the majority opinion 5 
was used. Variability of interpretation was assessed by calculating average agreement 6 
and kappa coefficient. 7 
Specimen collection, processing and testing 8 
Haematology and biochemistry 9 
Full blood count was performed on whole blood specimens using a Beckman Coulter HmX 10 
Haematology Analyser (Beckman Coulter, California, USA). Whole blood specimens for 11 
biochemical assays were centrifuged within 24 hours of collection. Urea and creatinine 12 
concentrations were measured in serum specimens using a Beckman Coulter AU480 13 
Chemistry Analyser (Beckman Coulter, California, USA). CD4 cell counts were measured 14 
using a Becton Dickinson FACSCount (Becton Dickinson, California, USA) or a Partec 15 
CyFlow CD4 Analyser (Sysmex Partec, Görlitz, Germany). 16 
Bacteriology 17 
Blood cultures were performed using standard aerobic bottles in the BacT/ALERT 3D 18 
automated system (bioMérieux, Marcy-L’Etoile, France) as previously described (E6). All 19 
isolates were identified using standard diagnostic procedures (E7). Coagulase-negative 20 
Staphylococci, Bacillus spp., Micrococcus spp. and diphtheroids were considered as 21 
contaminants.  22 
Urine was collected in standard containers and refrigerated. The BinaxNOW® urine 23 
antigen test for Streptococcus pneumoniae (Alere, Massachusetts, USA) was performed in 24 
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accordance with the manufacturer’s instructions (E8). The same procedure was applied 1 
for pleural fluid specimens. The BinaxNOW® test for Legionella pneumophila urinary 2 
antigen was performed on urine specimens that had been stored at -80°C following 3 
collection.  4 
Respiratory pathogen multiplex PCR 5 
The nasopharyngeal aspirate (NPA) specimens were refrigerated immediately following 6 
collection and then divided into aliquots before being stored at -80°C in Universal 7 
Transport Medium (Copan, Brescia, Italy) for later batch-testing. Total nucleic acids were 8 
extracted from 300μl aliquots of each specimen with the Qiagen BioRobotÒ Universal 9 
System using the QIAamp One-For-All nucleic acid kit (Qiagen, Manchester, UK). Influenza 10 
A and B viruses were detected by real-time reverse transcription polymerase chain 11 
reaction (qRT-PCR) using the CDC Human Influenza RT-PCR diagnostic panel (CDC 12 
Influenza Division) (E9). Adenovirus, bocavirus, Chlamydia pneumoniae, coronaviruses 13 
229E, HKU1, OC43 and NL63, enterovirus, human metapneumovirus (hMPV), 14 
Mycoplasma pneumoniae, parainfluenza virus types 1, 2, 3 and 4, parechovirus, 15 
respiratory syncytial viruses (RSV) and rhinovirus were detected using the FTD Respiratory 16 
Pathogens 33 kit (Fast-track Diagnostics, Luxembourg) (E10). The results for the other 17 
organisms detected by the FTD 33 kit were disregarded. 5 or 10 μL of nucleic acid extract 18 
was used in each qRT-PCR reaction in combination with the AgPath one-step RT-PCR 19 
reagents (Applied Biosystems, Foster City, California, USA). For both kits, PCR conditions 20 
were according to the manufacturer’s instructions. For the CDC Human Influenza RT-PCR 21 
diagnostic panel, samples with cycle threshold (Ct)-value <40 were recorded as positive; 22 
for the FTD 33 kit a cycle threshold (Ct)-value <33 was regarded as positive. Appropriate 23 
negative and positive control specimens were run alongside each reaction.  24 
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Mycobacterial diagnostic tests 1 
Sputum and pleural fluid microscopy were performed according to standard procedures. 2 
Briefly, the most viscous part of the sputum specimen was aspirated and expelled onto a 3 
dry glass slide, spread to make a thin smear and stained using the Auramine O method. 4 
Pleural fluid specimens were concentrated by centrifugation prior to smear preparation. 5 
Smear specimens were each examined twice by two independent readers using LED 6 
fluorescence microscopy and reported according to standard criteria; discordant results 7 
prompted review by a third reader. All sample smears graded as scanty, 1+, 2+, and 3+ 8 
were defined as acid-fast bacilli (AFB) smear-positive. 9 
Mycobacterial culture was performed according to standard procedures using the 10 
BACTEC MGIT 960 Mycobacterial Detection System (Becton Dickinson Diagnostic Systems, 11 
Sparks, Maryland, USA) as previously described (E11, E12). Briefly, following 12 
decontamination in sodium hydroxide and concentration by centrifugation, sputum and 13 
pleural fluid specimens were inoculated into mycobacterial growth indicator tubes (MGIT) 14 
tubes and incubated at 37°C in the BACTEC MGIT automated liquid culture system for up 15 
to 44 days. Cultured isolates identified as AFB on ZN microscopy were positively 16 
confirmed as Mycobacterium tuberculosis complex by microscopic cording and MPT-64 17 
lateral flow assay (Capilia; TAUNS Laboratories, Numazu, Japan). AFB isolates that were 18 
negative on either confirmatory test were inoculated onto plain Löwenstein-Jensen (LJ) 19 
media and incubated at 25°C, 37°C and 45°C and onto paranitrobenzoic acid (PNB) and 20 
incubated at 37°C. Isolates that grew on LJ media at 37°C only were classified as M. 21 
tuberculosis. Those that grew at 25°C or 45°C or on PNB were classified as 22 
nontuberculous mycobacteria and not speciated further. Positive cultures that did not 23 
reveal AFB on microscopy were re-cultured using a stored aliquot of the primary 24 
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specimen; if the same result was obtained, they were classified as contaminants or false 1 
positives.  2 
The Cepheid Xpert MTB/RIF assay (Cepheid, Sunnyvale, California, USA) is a self-3 
contained, fully integrated, automated rapid diagnostic system that uses nested real-time 4 
PCR to detect M. tuberculosis genomic DNA in sputum and other clinical specimens (E13). 5 
The assay was performed in accordance with the manufacturer’s instructions (E14). 6 
Assignment of aetiology 7 
A bacterial pathogen was determined to be present if: i) detected on blood or pleural 8 
fluid culture; ii) S. pneumoniae antigen was detected in urine or pleural fluid; iii) L. 9 
pneumophila antigen was detected in urine; or iv) C. pneumoniae or M. pneumoniae was 10 
detected by PCR in NPA. Certain bacterial blood culture isolates were considered to be 11 
contaminants. Mycobacterial infection was determined to be present if detected in 12 
sputum or pleural fluid by mycobacterial culture; or if Mycobacterium tuberculosis was 13 
detected by Xpert MTB/RIF assay. Positive AFB smear microscopy of sputum or pleural 14 
fluid in the absence of positive culture or Xpert MTB/RIF assay was assumed to be M. 15 
tuberculosis infection. Respiratory viral diagnosis was based on detection by PCR in NPA. 16 
Data management 17 
The clinical data were collected in paper-based CRFs and subsequently converted to 18 
electronic form using Intelligent Character Recognition scanning software (TeleForm; 19 
Cardiff Software Developers, Cardiff, UK). Prior to scanning the CRFs were checked by the 20 
clinical team and subsequently by study investigators (SA, AH, HJ and JH) and any 21 
discrepancies were queried. Automated validation checks were built in to the character 22 
recognition scanning process to identify outliers and erroneous values. Once all data were 23 
entered into the study database, further systemic data checks were performed to detect 24 
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potential errors, which were checked and corrected to create a final dataset. 1 
Statistical methods 2 
Statistical analyses were performed with Stata version 12.1 (StataCorp; Texas, US). The 3 
statistical methods for comparing microbial aetiology by radiographic and HIV status and 4 
for identifying independent risk factors for 30-day mortality are detailed in the main 5 
manuscript. The association of microbial aetiology with 30-day mortality for the most 6 
commonly identified pathogens (i.e. S. pneumoniae, M. tuberculosis and influenza) was 7 
estimated by multivariable logistic regression analysis with age, sex and HIV status 8 
included as covariates.  9 
The inter-observer variability of chest radiograph interpretation between the three 10 
readers was assessed by calculating average percentage agreement and kappa coefficient 11 
with estimated 95% confidence intervals (E15, E16). The kappa coefficient was 12 
interpreted as follow: <0, poor agreement; 0-0.2, slight agreement; 0.21-0.4, fair 13 
agreement; 0.41-0.6, moderate agreement; 0.61-0.8, substantial agreement; 0.81-1.0, 14 
almost perfect agreement. 15 
CAP severity assessment tools 16 
The following CAP severity-assessment tools were calculated as published and their 17 
prognostic performance to predict 30-day mortality was assessed.  18 
• CURB65: One point awarded for each of the following components present: 19 
confusion; urea >7 mmol/L; respiratory rate t30/min; systolic blood pressure <90 20 
mmHg or diastolic blood pressure d60 mmHg; age t65 years (E17). 21 
• CRB65: Derived as per CURB65 with the exclusion of urea >7 mmmol/L (E17). 22 
• SMRT-CO: Summation of points for each of the following components present: 23 
systolic blood pressure <90 mmHg (2 points); multilobar involvment (1 point); 24 
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respiratory rate t25/min if d50 years or t30/min if >50 years (1 point); heart rate 1 
t125/min (1 point); confusion (1 point); oxygen saturations d93% if d50 years or 2 
d90% if >50 years (2 points; E18). 3 
• Modified IDSA/ATS minor criteria: One point awarded for each of the following 4 
components present: respiratory rate t30/min; oxygen saturations d90% (used as 5 
a surrogate for arterial oxygen pressure/fraction of inspired oxygen (PaO2/FiO2) 6 
ratio d250 criterion included in the published tool); multilobar infiltrates; 7 
confusion/disorientation; urea t7.1 mmol/L; white blood cell count <4 x109 8 
cells/L; platelets <100 x109 cells/L; temperature <36qC; systolic blood pressure < 9 
90 mmHg (used as a surrogate for hypotension requiring aggressive fluid 10 
resuscitation; E19). 11 
• SWAT-Bp: One point awarded for each of the following components present: male 12 
sex; wasting; non-ambulatory status; temperature <35qC or >38qC; systolic blood 13 
pressure <100 mmHg or diastolic blood pressure <60 mmHg (E20). 14 
To calculate the prognostic performance characteristics of severity assessment tool, 15 
the recommended cutoffs used to define “severe pneumonia” were used: CURB65 t3; 16 
CRB65 t2; SMRT-CO t2; modified IDSA/ATS minor criteria t3; and SWAT-Bp t3. For 17 
each severity score, sensitivity, specificity, positive and negative predictive values, 18 
positive and negative likelihood ratios and area under the receiver-operating 19 
characteristic curve with 95% confidence intervals were calculated using standard 20 
methods. Patients with incomplete data were excluded from the analysis.  21 
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SUPPLEMENTAL RESULTS 1 
Supplemental Table E1. Demographic, clinical and radiographic characteristics of 459 2 
Malawian adults hospitalised with community-acquired pneumonia. 3 
Characteristic No. (%) of episodes 
Demographics   
Male sex 285/459 (62.1) 
Age (yrs)* 
18-24 
25-34 
35-44 
45-54 
56-64 
≥65  
34.7 
53/459 
185/459 
136/459 
43/459 
24/459 
18/459 
(29.4-41.9) 
(11.6) 
40.3) 
(29.6) 
(9.4) 
(5.2) 
(3.9) 
Socioeconomic factors   
Employment status 
Paid employment 
Self-employed 
Unemployed 
Other 
 
157/455 
152/455 
120/455 
26/455 
 
(34.5) 
(33.4) 
(26.4) 
(5.7) 
Highest educational level attended 
None 
Primary 
Secondary 
Higher 
 
45/451 
242/451 
152/451 
12/451 
 
(10.0) 
(53.7) 
(33.7) 
(2.7) 
Main household water source 
River 
Borehole/well 
Public tap/standpipe 
Piped to dwelling 
 
3/458 
128/458 
247/458 
80/458 
 
(0.7) 
(28.0) 
(53.9) 
(17.5) 
Difficulty obtaining food 
Often 
Sometimes 
Never 
 
35/458 
202/458 
221/458 
 
(7.6) 
(44.1) 
(48.3) 
Main cooking fuel 
Firewood 
Charcoal 
Paraffin 
Electricity 
 
117/458 
298/458 
6/458 
37/458 
 
(25.6) 
(65.0) 
(1.3) 
(8.1) 
HIV status   
HIV positive† 
Newly diagnosed 
355/453 
124/355 
(78.4) 
(34.9) 
CD4 cell count (cells/mm3)† 
All HIV-positive* 
<50 
50-199 
≥200 
Newly diagnosed HIV-positive* 
 
99 
88/315 
158/315 
69/315 
93 
 
(44-193) 
(27.9) 
(50.2) 
(21.9) 
(43-179) 
ART use in known HIV-positive† 189/227 (83.3) 
ART duration† 
<3 months 
3-12 months 
>12 months 
 
34/157 
35/157 
89/157 
 
(21.7) 
(22.3) 
(56.1) 
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Characteristic No. (%) of episodes 
CPT use on admission† 
All HIV-positive 
Known HIV-positive 
 
151/355 
151/188 
 
(42.5) 
(80.3) 
Medical history   
Any other comorbid condition 31/451 (6.9) 
Chronic lung disease‡ 15/452 (3.3) 
Chronic heart disease§ 3/452 (0.7) 
Hypertension 8/452 (1.8) 
Cancer 5/452 (1.1) 
Chronic kidney disease 1/452 (0.2) 
Liver disease 1/452 (0.2) 
Stroke 5/452 (1.1) 
Epilepsy 1/452 (0.2) 
Dementia 2/452 (0.4) 
Previous tuberculosis ll 84/458 (18.3) 
Previous pneumonia in last 5 years** 108/457 (23.6) 
Pregnancy 2/174 (1.2) 
Current smoker 50/457 (10.9) 
Regular alcohol intake 122/456 (26.8) 
Pre-hospital attendance & treatment   
Pre-admission symptom duration* 
1-3 days 
4-7 days 
8-10 days 
11-14 days 
7 
63/457 
214/457 
50/457 
130/457 
(5-12) 
(13.8) 
(46.8) 
(10.9) 
(28.5) 
Travel time to hospital 
<1 hour 
1-2 hours 
>2 hours 
 
114/455 
245/455 
96/455 
 
(25.0) 
(53.9) 
(21.1) 
Attended another health facility†† 283/458 (61.8) 
Prior review 
Primary health centre 
Private clinic 
Other hospital 
Pharmacy 
Traditional healer 
283/458 
230/283 
49/283 
7/283 
1/283 
2/283 
(61.8) 
(81.2) 
(17.3) 
(2.5) 
(0.4) 
(0.7) 
Antibiotics within 2 weeks‡‡ 280/455 (61.5) 
Antimalarials within 2 weeks 79/457 (17.3) 
Traditional remedies within 2 weeks 40/456 (8.8) 
Clinical features   
Symptoms 
Cough 
Sputum production 
Dyspnoea 
Fever 
Weight loss 
Night sweats 
 
451/458 
357/458 
440/458 
457/458 
277/458 
299/457 
 
(98.5) 
(78.0) 
(96.1) 
(99.8) 
(60.5) 
(65.4) 
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Characteristic No. (%) of episodes 
Examination features 
Crepitations 
Bronchial breathing 
Pleural effusion 
Confusion/disorientation 
Inability to stand 
Oral thrush 
Kaposi’s sarcoma 
 
387/457 
167/458 
79/457 
5/458 
87/459 
28/458 
14/458 
 
(84.7) 
(36.4) 
(17.3) 
(1.1) 
(19.0) 
(6.1) 
 (3.1) 
Baseline laboratory results   
Haemoglobin (g/dL)* 
<8 
11 
74/449 
(9.0-12.8) 
(16.5) 
White blood cells (x 109 cells/L)* 
<4 
≥15 
7.7 
67/448 
x63/448 
(5.0-11.4) 
(15.0) 
(14.1) 
Urea (mmol/L)* 
>7 
4.8 
137/450 
(3.3-8.0) 
(30.4) 
Creatinine (μmol/L)* 
>120 
76 
76/448 
(59-100) 
(17.0) 
Radiological features§§   
Radiographic pneumonia 317/417 (76.0) 
Consolidation 251/313 (80.2) 
Multilobar involvement 73/247 (29.6) 
Cavitation 20/317 (6.3) 
Pleural effusion 118/315 (37.5) 
Outcomellll   
Inpatient mortality 51/457 (11.2) 
Day 30 mortality 64/439 (14.6) 
Day 90 mortality 87/418 (20.8) 
Definition of abbreviations: ART = antiretroviral therapy; BP = blood pressure; CPT = 
co-trimoxazole preventative therapy; IQR = interquartile range. 
Data are n/N (%) unless indicated by * where median and interquartile range are 
shown.  Variation in denominator reflects missing data unless further specified. 
†HIV status missing in 6 patients; CD4 count missing in 40 of all with HIV; CPT and 
ART usage missing in 4 and 43, respectively, with known HIV; ART duration missing 
in 32 reporting ART use. 
‡Chronic lung disease includes asthma, COPD and bronchiectasis.  
§Chronic heart disease includes congestive cardiac failure, cor pulmonale and 
dilated cardiomyopathy.  
llAny previous episode of treated tuberculosis regardless of site and confirmation.  
**Any prior episode within the last 5 years of a syndrome compatible with lower 
respiratory tract infection reviewed in a healthcare facility and treated with 
antibiotics.  
††Included attendance to other hospital, health centre, private clinic, traditional 
healer or pharmacy.  
‡‡Excluded co-trimoxazole prophylaxis in HIV-infected individuals. 
§§Chest radiographs available in 421 patients; reports based on consensus grading 
of assessors and denominator may vary when consensus not obtained.   
llllStatus at hospital discharge, day 30 and day 90 missing in 2, 20 and 41, 
respectively. 
 1 
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Supplem
ental Table E2. Radiological features w
ith inter-report agreem
ent in M
alaw
ian adults hospitalised w
ith com
m
unity-acquired 
pneum
onia.  
 
Individual scorer’s assessm
ent 
Consensus 
interpretation
† 
A
ll scorer’s agreem
ent 
 
Radiologist 1 
(n=419) * 
Radiologist 2 
(n=407) * 
Clinician 
(n=417) * 
Avg. agree (%
) ‡ 
Kappa (95%
 CI)  ‡ 
Radiographic pneum
onia 
323 (77.1) 
297 (73.0) 
314 (75.3) 
317/417 (76.0) 
90.6 
0.75 (0.69-0.81) 
Any parenchym
al abnorm
ality 
300 (71.6) 
266 (65.3) 
268 (64.3) 
282/414 (68.1) 
86.0 
0.68 (0.61-0.74) 
Consolidation 
245 (58.5) 
251 (61.7) 
260 (62.4) 
251/413 (60.8) 
83.3 
0.65 (0.59-0.70) 
Quality 
Confluent 
Patchy 
 
159/244 
85/244  (65.2) 
(34.9) 
 
135/251 
116/251  (53.8) 
(46.2) 
 
161/260 
99/260  (61.9) 
(38.1) 
 
145/233
 
88/233  (62.2) 
(37.8) 
74.5 
0.46 (0.37-0.55) 
Extent 
Segm
ental 
Lobar 
M
ultifocal 
 
77/245 
73/245 
95/245  (31.4) 
(29.8) 
(38.8) 
 
78/250 
73/250 
99/250  (31.2) 
(29.2) 
(39.6) 
 
83/260 
89/260 
88/260  (31.9) 
(34.2) 
(33.9) 
 
62/225
  
73/225
  
90/225
   (27.6) 
(32.4) 
(40.0) 
 
65.9 
 
0.48  (0.42-0.56) 
M
ultilobar 
85/255 (34.7) 
65/251 (25.9) 
76/260 (29.2) 
73/247 (29.6) 
83.3 
0.55  (0.46-0.63) 
Cavitation 
27/417 (6.5) 
26/406 (6.4) 
15/416 (3.6) 
20/418 (4.8) 
94.9 
0.51 (0.35-0.65) 
Reticulonodular change 
140 (33.4) 
35 (8.6) 
24 (5.8) 
35/418 (8.4) 
76.9 
0.15 (0.07-0.24) 
M
iliary appearance 
2/414 (0.5) 
2/405 (0.5) 
8/416 (1.9) 
2/417 (0.5) 
98.4 
0.17 (-0.01-0.34) 
Pleural effusion 
111 (26.5) 
106 (26.0) 
155 (37.2) 
118/416 (28.4) 
83.7 
0.61 (0.55-0.67) 
Pneum
othorax 
2/410 (0.5) 
1/406 (0.3) 
3/405 (0.7) 
2/416 (0.5) 
99.3 
0.32 (-0.02-0.49) 
M
ediastinal lym
phadenopathy 
40 (9.6) 
34 (8.4) 
50 (12.0) 
28/417 (6.7) 
87.4 
0.30 (0.19-0.42) 
Volum
e loss 
76 (18.1) 
35 (8.6) 
44 (10.6) 
30/421 (7.1) 
84.1 
0.28 (0.17-0.38) 
Bronchiectasis 
31 (7.4) 
8 (2.0) 
3 (0.7) 
3/421 (0.7) 
93.7 
0.03 (-0.04-0.11) 
Definition of abbreviations: CI = confidence interval.  
Data are n/N (%
) unless otherw
ise specified. Chest radiographs w
ere available in 421 of 459 patients; chest radiographs unavailable because of death prior to 
radiograph (n=14), hospital discharge w
ithout radiograph or prior to digital capture (n=18) and unclear reason (n=6).  
*Radiologist 1, radiologist 2 and clinician considered 2, 14 and 4 radiographs, respectively, as uninterpretable.  
†Consensus values calculated by m
ajority rating of all assessors; denom
inator m
ay vary w
hen consensus not obtained, m
ost notably for specific features of 
consolidation w
hich w
ere reported only w
hen assessor regarded consolidation as present.  
‡Average agreem
ent and three-w
ay kappa (estim
ated 95%
 confidence intervals) calculated for all three assessors.   
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Supplemental Table E3. Clinical features and outcome by chest radiograph availability and 
radiographic status in Malawian adults hospitalised with community-acquired 
pneumonia.  
Characteristic 
Chest radiograph available (n=417) 
Chest radiograph  
unavailable 
(n=38) 
P‡ Radiographic 
pneumonia  
(n=317) 
No radiographic 
pneumonia  
(n=100) 
P† 
Male sex 210/317 (66.3) 59/100 (49.0) 0.002 23/38 (60.5) 0.85 
Age* 35 (30-42) 33 (27-38) 0.01§ 37 (30-44) 0.22§ 
HIV positivell 247/313 (78.9) 73/98 (74.5)) 0.36 31/38 (81.6) 0.60 
Pre-presentation symptoms  
>7 days 
122/316 (38.6) 42/103 (42.0) 0.55 15/37 (40.5) 0.90 
Temperature <35 or ≥40 °C 10/317 (3.2) 3/100 (3.0) 1.00** 1/38 (2.6) 1.00** 
Systolic BP <90 mmHg 61/314 (19.4) 13/99 (13.1) 0.15 11/37 (29.7) 0.08 
Diastolic BP ≤60 mmHg 98/314 (31.2) 26/99 (26.3) 0.35 16/37 (43.2) 0.10 
Heart rate ≥125 /min 127/316 (40.2) 35/100 (54.0) 0.35 14/38 (36.8) 0.80 
Respiratory rate ≥30 /min 155/307 (50.5) 36/98 (36.7) 0.02 18/37 (48.7) 0.86 
Oxygen saturations <90 % 52/308 (16.9) 7/100 (7.0) 0.02 13/38 (34.2) 0.002 
BMI <18.5 kg/m2 94/306 (30.7) 28/98 (28.6) 0.69 10/37 (27.0) 0.69 
Inability to stand 51/317 (16.1) 18/100 (18.0) 0.65 16/38 (42.1) <0.001 
Haemoglobin <8 g/dL 45/313 (14.4) 22/96 (22.9) 0.048 6/37 (16.2) 0.98 
White blood cells <4 x109 /L 41/312 (13.1) 19/96 (19.8) 0.11 7/37 (18.9) 0.49 
Urea >7 mmol/L 98/313 (31.3) 27/98 (27.6) 0.48 12/37 (32.4) 0.80 
Creatinine >120 μmol/L 46/313 (14.7) 22/96 (22.9) 0.06 7/37 (18.9) 0.72 
Day 30 mortality 31/304 (10.2) 16/98 (16.3) 0.10 17/36 (47.2) <0.001 
Definition of abbreviations: BMI = body mass index; BP = blood pressure 
Data are n/N (%) unless indicated by * where median and interquartile range are shown. Variation in denominator 
compared to column header reflecting missing data. 
†Comparison between patients with and without radiographic pneumonia by χ2 test unless otherwise stated.  
‡Comparison between all patients with and all without available interpretable chest radiograph by χ2 test unless otherwise 
stated; 4 patients who had chest radiograph but without consensus interpretation excluded from analysis.  
§Wilcoxon rank-sum test 
llHIV status missing in 6 patients 
**Fisher’s exact test 
††Status at day 30 missing in 19 patients. 
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Supplemental Table E4. Intravenous antibiotic treatment duration, length of stay and 30-
day mortality by antibiotic treatment group in Malawian adults hospitalised with 
community-acquired pneumonia.  
Antibiotic treatment group n Intravenous antibiotic 
duration, days 
Median (IQR) 
Length of stay, days 
Median (IQR) 
30-day mortality 
n/N (%) 
Ceftriaxone monotherapy 251/450 (55.8) 5 (3-7) 7 (4-9) 38/242 (15.7) 
Ceftriaxone-based 
combination  
114/450 (25.3) 5 (3-7) 8 (5-11) 15/108 (13.9) 
Penicillin & Chloramphenicol 65/450 (14.4) 4 (3-6) 6 (4-8) 8/61 (13.1) 
Penicillin & Chloramphenicol-
based combination 
15/450 (3.3) 3 (2-7) 12 (4-18) 0/14 (0) 
Amoxicillin (oral) 5/450 (1.1) - - 9 (5-11) 1/5 (20) 
Definition of abbreviations: IQR = interquartile range. 
Patients assigned to treatment group on the basis of all antibiotics prescribed during admission, excluding anti-tuberculous 
treatment. Patients in ‘combination’ groups received additional intravenous and/or oral agents. Data missing in 8 patients.  
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Supplemental Table E5. Organism identification by specimen type and diagnostic test 
stratified by HIV status.  
Organism All
* 
(n=459) 
HIV-positive 
(n=355) 
HIV-negative 
(n=98) 
Blood cultures† 
Streptococcus pneumoniae 5/450 (1.1) 4/350 (1.1) 1/94 (1.1) 
Salmonella Typhi 9/450 (2.0) 3/350 (0.9) 5/94 (5.3) 
Salmonella Typhimurium 6/450 (1.3) 6/350 (1.7) 0/94 (0) 
Salmonella Enteritidis 1/450 (0.2) 1/350 (0.3) 0/94 (0) 
Staphylococcus aureus 2/450 (0.4) 1/350 (0.3) 1/94 (1.1) 
Escherichia coli 2/450 (0.4) 2/350 (0.6) 0/94 (0) 
Enterobacter cloacae 1/450 (0.2) 1/350 (0.3) 0/94 (0) 
Pleural fluid culture 
Salmonella Typhi 1/31 (3.2) 1/19 (5.3) 0/11 (0) 
Mycobacterium tuberculosis 7/35 (20.0) 4/22 (18.2) 2/12 (16.7) 
Streptococcus pneumoniae antigen test 
Urine 95/433 (21.9) 67/333 (20.1) 28/94 (29.8) 
Pleural fluid 3/31 (9.7) 1/20 (5) 2/10 (20) 
Legionella pneumophila antigen test 
Urine 0/193 (0) 0/154 (0) 0/38 (0) 
Sputum mycobacterial diagnostic tests 
AFB smear microscopy 36/305 (11.8) 30/241 (12.4) 6/60 (10.0) 
Sputum culture 
Mycobacterium tuberculosis 60/273 (22.0) 54/217 (24.9) 6/52 (11.5) 
NTM 8/273 (2.9) 5/217 (2.3) 3/52 (5.8) 
Xpert MTB/RIF 56/308 (18.2) 46/244 (18.9) 10/60 (16.7) 
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Organism All (n=459) 
HIV-positive 
(n=355) 
HIV-negative 
(n=98) 
Multiplex PCR on nasopharyngeal aspirate 
Adenovirus 35/455 (7.7) 30/355 (8.5) 5/98 (5.1) 
Bocavirus 13/455 (2.9) 13/355 (3.6) 0/98 (0) 
Chlamydia pneumoniae 2/455 (0.4) 0/355 (0) 2/98 (2) 
Coronavirus HKU1 3/455 (0.7) 3/355 (0.9) 0/98 (0) 
Coronavirus 229E 19/455 (4.2) 16/355 (4.5) 3/98 (3.1) 
Coronavirus OC43 6/455 (1.3) 6/355 (1.7) 0/98 (0) 
Coronavirus NL63 5/455 (1.4) 5/355 (1.4) 0/98 (0) 
Enterovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 
Influenza A 19/454 (4.2) 13/354 (3.7) 5/98 (5.1) 
Influenza B 21/454 (4.6) 17/354 (4.8) 4/98 (4.1) 
Metapneumovirus 9/455 (2) 8/355 (2.3) 1/98 (1.0) 
Mycoplasma pneumoniae 6/455 (1.3) 6/355 (1.7) 0/98 (0) 
Parainfluenza 1 2/455 (0.4) 1/355 (0.3) 1/98 (1.0) 
Parainfluenza 2 6/455 (1.3) 6/355 (1.7) 0/98 (0) 
Parainfluenza 3 7/455 (1.5) 7/355 (2) 0/98 (0) 
Parainfluenza 4 3/455 (0.7) 2/355 (0.6) 0/98 (0) 
Parechovirus 5/455 (1.1) 5/355 (1.4) 0/98 (0) 
Rhinovirus 17/455 (3.7) 15/355 (4.2) 2/98 (2) 
RSV 8/455 (1.8) 4/355 (1.1) 3/98 (3.1) 
Definition of abbreviations: NTM = nontuberculous mycobacteria; RSV = respiratory syncytial virus.  
Data are n/N (%) specimens positive for specific organism; variation in denominator reflects the 
availability of the relevant clinical specimen. 
*In the 6 patients with unknown HIV status the following positive results were obtained: blood culture - S. 
Typhi, 1; pleural fluid culture – M. tuberculosis, 1; nasopharyngeal aspirate PCR – 1 each of influenza A, 
parainfluenza and RSV. 
†A further 12 blood cultures (3%) yielded organisms regarded as contaminants: coagulase-negative 
Staphylococci, 8; Micrococcus spp., 2; Bacillus spp., 2. 
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Supplem
ental Table E6. Aetiology of com
m
unity-acquired pneum
onia in M
alaw
ian adults stratified by radiological appearance and HIV status.  
 
Radiographic pneum
onia (n=317) * 
No radiographic pneum
onia (n=100) * 
 
Organism
 
All 
HIV-pos. 
HIV-neg. 
All 
HIV-pos. 
HIV-neg. 
P for difference
† 
Streptococcus pneum
oniae 
83/316 (26.3) 
56/247 (22.7) 
27/65 (41.5) 
8/100 (8.0) 
5/73 (6.9) 
3/25 (12) 
<0.001 
Salm
onella Typhi 
2/309 (0.7) 
2/243 (0.8) 
0/62 (0) 
8/99 (8.1) 
2/72 (2.8) 
5/25 (20) 
<0.001 
Nontyphoidal Salm
onella
‡ 
1/309 (0.3) 
1/243 (0.4) 
0/62 (0) 
5/99 (5.1) 
5/72 (6.9) 
0/25 (0) 
<0.001 
Other GNEB
§ 
2/309 (0.7) 
2/243 (0.8) 
0/62 (0) 
1/99 (1) 
1/72 (1.4) 
0/25 (0) 
0.66 
S. aureus 
1/309 (0.3) 
0/243 (0) 
1/62 (1.6) 
0/99 (0) 
0/72 (0) 
0/25 (0) 
0.53 
Atypical bacteria
ll 
5/314 (1.6) 
4/247 (1.6) 
1/66 (1.5) 
1/99 (1) 
0/73 (0) 
1/25 (4) 
0.66 
M
ycobacterium
 tuberculosis 
58/232 (25) 
47/186 (25.3) 
10/42 (23.8) 
13/68 (19.1) 
13/50 (26) 
0/17 (0) 
0.39 
NTM
 
3/194 (1.6) 
2/158 (1.3) 
1/33 (3) 
4/57 (7.0) 
2/41 (4.9) 
2/15 (13.3) 
0.046 
Influenza 
25/313 (8) 
20/246 (8.1) 
4/66 (6.1) 
11/99 (11.1) 
9/73 (12.3) 
2/25 (8) 
0.26 
Adenovirus 
22/314 (7) 
19/247 (7.7) 
3/66 (4.5) 
7/99 (7.1) 
5/73 (6.9) 
2/25 (8) 
0.95 
Coronavirus 
22/314 (7) 
19/247 (7.7) 
3/66 (4.6) 
9/99 (9.1) 
9/73 (12.3) 
0/25 (0) 
0.43 
Parainfluenza 
10/314 (3.2) 
9/247 (3.6) 
1/66 (1.5) 
6/99 (6.1) 
5/73 (6.9) 
0/25 (0) 
0.34 
Rhinovirus 
11/314 (3.5) 
9/247 (3.6) 
2/66 (3) 
4/99 (4) 
4/73 (5.5) 
0/25 (0) 
0.76 
Bocavirus 
9/314 (2.9) 
9/247 (3.6) 
0/66 (0) 
3/99 (3) 
3/73 (4.1) 
0/25 (0) 
0.85 
M
etapneum
ovirus 
9/314 (2.9) 
8/247 (3.2) 
1/66 (1.5) 
0/99 (0) 
0/73 (0) 
0/25 (0) 
0.09 
RSV 
4/314 (1.3) 
1/247 (0.4) 
2/66 (3) 
3/99 (3) 
2/73 (2.7) 
1/25 (4) 
0.16 
Enterovirus 
2/314 (0.6) 
2/247 (0.8) 
0/66 (0) 
1/99 (1) 
1/73 (1.4) 
0/25 (0) 
0.66 
Parechovirus 
2/314 (0.6) 
2/247 (0.8) 
0/66 (0) 
1/99 (1) 
1/73 (1.4) 
0/25 (0) 
0.66 
No pathogen detected 
123/317 (38.8) 
95/247 (38.5) 
26/66 (39.4) 
37/100 (37) 
25/73 (34.3) 
11/25 (48) 
0.85 
Definition of abbreviations: GNEB = Gram
-negative enteric bacilli; NTM
 = nontuberculous m
ycobacteria; RSV = respiratory syncytial virus.  
Data are n/N (%
). Denom
inators indicate num
ber of patients w
ith at least one relevant test available. S. pneum
oniae diagnosis based on com
bination of blood and pleural fluid 
culture and antigen assay of urine and pleural fluid. M
. tuberculosis based on com
bination of sputum
 m
icroscopy, culture and Xpert M
TB/RIF and pleural fluid culture. Other 
organism
s based on single test. *In the 42 patients w
ithout available chest radiograph or consensus report for radiographic pneum
onia, the follow
ing organism
s w
ere detected: S. 
pneum
oniae, 7; nontyphoidal Salm
onella, 1; S. aureus, 1; atypical bacteria, 2; M
. tuberculosis, 4; NTM
, 1; influenza, 4; adenovirus, 6; parainfluenza, 1; rhinovirus, 2; bocavirus, 1; 
RSV, 1; enterovirus, 2; parechovirus, 2; no pathogen detected, 21. †Association of organism
 w
ith radiological appearance controlling for effect of HIV by M
antel-H
aenszel χ 2 test. 
‡S. Enteritidis and S. Typhim
urium
 com
bined. §Escherichia coli and Enterobacter cloacae com
bined.  ll Chlam
ydia pneum
oniae and M
ycoplasm
a pneum
oniae com
bined.  
CAP in Malawian adults – Online Data Supplement 
 20 
Supplemental Table E7. Radiological features of community-acquired pneumonia in 
Malawian adults stratified by microbial aetiology.  
Radiographic feature* 
Organism 
Streptococcus 
pneumoniae†  
(n=69) 
Mycobacterium 
tuberculosis‡ 
(n=51) 
Influenza 
(n=16)§ 
Any parenchymal abnormality 65/68 (95.6) 43/51 (84.3) 16/16 (100) 
Consolidation 61/68 (89.7) 40/51 (78.4) 11/16 (68.8) 
Quality§ 
Confluent 
Patchy 
 
46/60 
14/60 
 
(76.7) 
(23.3) 
 
17/37 
20/37 
 
(46.0) 
(54.1) 
 
4/9 
5/9 
 
(44.4) 
(55.6) 
Extent§ 
Segmental 
Lobar 
Multifocal 
 
11/57 
23/57 
23/57 
 
(19.3) 
(40.4) 
(40.4) 
 
5/37 
8/37 
24/37 
 
(13.5) 
(21.6) 
(64.9) 
 
1/8 
3/8 
4/8 
 
(12.5) 
(37.5) 
(50.0) 
Multilobar 20/61 (32.8) 20/51 (39.2) 3/14 (21.4) 
Cavitation 2/69 (2.9) 6/51 (11.8) 0/16 (0) 
Reticulonodular change 4/69 (5.8) 14/51 (27.5) 3/16 (18.8) 
Miliary appearance 0/69 (0) 0/50 (0) 0/16 (0) 
Pleural effusion 22/69 (31.9) 23/50 (46.0) 3/16 (18.8) 
Mediastinal lymphadenopathy 2/69 (2.9) 8/51 (15.7) 1/16 (6.3) 
Data area n/N (%). Analysis restricted to patients with radiographic pneumonia who did not have co-infection 
involving more than one of S. pneumoniae, M. tuberculosis and influenza to achieve three mutually exclusive 
groups.  
*Based on consensus values of all assessors; denominator may vary when consensus not obtained.  
†Additional 6 patients with M. tuberculosis and 7 with influenza co-infection excluded. Other co-infections 
detected in 24: bacterial, 5; viral, 18; mixed viral-non-tuberculous mycobacterial, 1.  
‡Additional 6 patients with S. pneumoniae and 1 with influenza co-infection excluded. Other co-infections 
detected in 15: bacterial, 2; viral, 11; mixed viral-bacterial, 2. 
§Additional 8 patients with S. pneumoniae and 1 with M. tuberculosis co-infection excluded. Other co-
infections detected in 4: bacterial, 1; viral, 3. 
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Supplemental Table E8. Matrix showing co-infection combinations in Malawian adults 
hospitalised with community-acquired pneumonia.  
 
S.
 p
ne
um
on
ia
e 
S.
 ty
ph
i 
NT
S 
Ot
he
r G
NE
B 
S.
 a
ur
eu
s 
At
yp
ica
l b
ac
te
ria
 
M
. t
ub
er
cu
lo
sis
 
NT
M
 
In
flu
en
za
 
Ad
en
ov
iru
s 
Co
ro
na
vir
us
es
 
Pa
ra
in
flu
en
za
 
Rh
in
ov
iru
s 
Bo
ca
vir
us
 
M
et
ap
ne
um
ov
iru
s 
RS
V 
En
te
ro
vir
us
 
Pa
re
ch
ov
iru
s 
TO
TA
L 
S. pneumoniae 40 0 0 0 0 0 7 2 6 7 5 4 6 1 3 2 0 0 73 
S. typhi  2 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 4 
NTS   2 0 0 0 0 2 0 1 1 1 0 0 0 0 0 0 5 
Other GNEB    0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 
S. aureus     0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 
Atypical bacteria      1 1 0 0 0 0 1 0 0 0 0 0 0 3 
M. tuberculosis       42 0 2 8 3 4 3 1 2 1 0 0 68 
NTM        2 0 2 2 1 1 0 0 0 0 0 8 
Influenza         19 1 3 1 1 1 0 1 0 0 31 
Adenovirus          8 1 1 0 0 1 0 0 0 23 
Coronaviruses           10 0 2 3 0 0 0 0 25 
Parainfluenza            4 2 0 1 0 0 0 14 
Rhinovirus             3 0 0 0 1 1 13 
Bocavirus              3 0 2 0 0 8 
Metapneumovirus               1 0 0 0 6 
RSV                2 0 0 7 
Enterovirus                 0 1 1 
Parechovirus                  0 1 
Definition of abbreviations: GNEB = Gram-negative enteric bacilli; NTM = nontuberculous mycobacteria; NTS 
= nontyphoidal Salmonella; RSV = respiratory syncytial virus. 
Analysis performed in 307 patients with complete results available for blood culture, pneumococcal urine 
antigen testing, sputum mycobacterial culture and/or Xpert MTB/RIF, nasopharyngeal aspirate multiplex 
PCR; 152 excluded for lacking results for one or more of these investigations. Darkly shaded squares indicate 
mono-infection. 
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Supplemental Table E9. Association of aetiology with 30-day mortality for three 
commonest pathogens in Malawian adults with community-acquired pneumonia.  
Organism 
30-day mortality 
No. (%) aOR (95% CI)* P 
Streptococcus pneumoniae 
Yes 
No 
 
7/94  
57/344  
  
(7.5) 
(16.6) 
 
0.40 (0.17-0.91) 
 
0.03 
Mycobacterium tuberculosis 
Yes 
No 
 
17/74  
22/241  
  
(23.0) 
(9.1) 
 
2.44 (1.19-5.01) 
 
0.02 
Influenza 
Yes 
No 
 
2/39  
61/396  
  
(5.1) 
(15.4) 
 
0.39 (0.09-1.67) 
 
0.20 
Definition of abbreviations: aOR = adjusted odds ratio; CI = confidence interval; 
IQR = interquartile range.  
Data are n/N (%). Status at day 30 determined in 439 of 459 patients overall; 
individual analyses for each pathogen restricted to those for whom relevant 
specimens available: S. pneumoniae (n=438); M. tuberculosis (n=315); 
influenza (n=435).  
*Odds ratios calculated by logistic regression and adjusted for age, sex and HIV 
status.  
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Supplemental Table E10. Association of candidate clinical and laboratory risk factors with 
30-day mortality in HIV-infected Malawian adults hospitalised with community-acquired 
pneumonia.  
Characteristic Day 30 survivors (n=288) 
Day 30 mortality 
(n=54) 
Univariable analysis Multivariable analysis 
OR (95% CI) P aOR (95% CI) P 
Male sex 170/288 (59.0) 45/54 (83.3) 3.47 (1.63-7.37) 0.001 1.94 (0.81-4.67) 0.14 
Age (yrs) 34 (30-41) 36 (32-41) 1.01 (0.98-1.03) 0.72 1.00 (0.96-1.04) 0.98 
Current smoker 23/286 (8.0) 3/54 (5.6) 0.67 (0.19-2.32) 0.53 - - 
Pre-presentation 
symptoms >7 days 99/288 (34.4) 32/53 (60.4) 2.91 (1.59-5.31) 0.001 3.56 (1.60-7.93) 
0.002 
Temperature <35 or ≥40 
°C 10/288 (3.5) 1/54 (1.9) 0.52 (0.07-4.18) 0.54 -
* - 
Systolic BP <90 mmHg 58/284 (20.4) 15/54 (27.8) 1.50 (0.77-2.90) 0.23 - - 
Heart rate ≥125 /min 117/287 (40.8) 33/54 (61.1) 2.28 (1.26-4.14) 0.007 3.06 (1.40-6.71) 0.005 
Resp. rate ≥30 /min) 128/277 (46.2) 28/53 (52.8) 1.30 (0.72-2.35) 0.38 - - 
Oxygen satn <90 % 33/282 (11.7) 23/54 (42.6) 5.60 (2.92-10.73) <0.0001 2.97 (1.28-6.88) 0.01 
MUAC <230 mm 82/285 (28.8) 13/53 (24.5) 0.80 (0.41-1.58) 0.53 - - 
Inability to stand 47/288 (16.3) 26/54 (48.2) 4.76 (2.57-8.84) <0.0001 4.25 (1.84-9.79) 0.001 
Haemoglobin <8 g/dL 51/283 (18.0) 17/51 (33.3) 2.27 (1.18-4.38) 0.01 - - 
White cell count  
<4 x 109/L 41/282 (14.5) 14/51 (27.5) 2.22 (1.11-4.47) 0.03 - 
- 
Platelets <100 x 109/L 48/283 (17.0) 11/51 (21.6) 1.34 (0.64-2.81) 0.43 - - 
Urea >7 mmol/L 90/285 (31.6) 22/50 (44.0) 1.70 (0.92-3.14) 0.09 - - 
CD4 count <50 cells/mm3 65/257 (25.3) 23/47 (48.9) 2.83 (1.50-5.35) 0.001 2.30 (1.07-4.92) 0.03 
Definition of abbreviations: BP = blood pressure; BMI = body mass index; CI = confidence interval; MUAC = mid-upper arm 
circumference; OR = odds ratio; Resp. = respiratory 
For age (in italics) data shown as median and interquartile range. Otherwise data shown as n/N (%) with variation in 
denominator compared to column header reflecting missing data. Univariable and multivariable analyses by logistic 
regression. For age, odds ratio indicates change in risk of mortality with each year increase. 13 of 355 HIV-infected 
patients within study cohort excluded due to unknown 30-day outcome. Final multivariable analysis based on 287 
patients with complete results for all included parameters.  
*Excluded from multivariable analysis because of prevalence ≤5%.  
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Supplemental Table E11. Association of clinical and laboratory risk factors with 30-day 
mortality in hospitalised Malawian adults with radiographic community-acquired 
pneumonia.  
 
Characteristic Day 30 survivors (n=274) 
Day 30 mortality 
(n=31) 
Univariable analysis Multivariable analysis 
OR (95% CI) P aOR (95% CI) P 
Male sex 179/274 (65.3) 24/31 (77.4) 1.82 (0.76-4.38) 0.18 1.39 (0.53-3.61) 0.51 
Age (yrs) 35 (30-42) 37 (32-44) 1.01 (0.98-1.03) 0.70 1.02 (0.98-1.05) 0.39 
Current smoker 28/272 (10.3) 3/31 (9.7) 0.93 (0.27-3.27) 0.92 - - 
Pre-presentation 
symptoms >7 days 99/273 (36.3) 19/31 (61.3) 2.78 (1.30-5.97) 0.009 3.30 (1.37-7.96) 
0.008 
HIV-positive 216/271 (79.7) 25/31 (80.7) 1.06 (0.41-2.71) 0.90 1.11 (0.36-3.42) 0.86 
Temperature <35 or 
≥40 °C 10/274 (3.7) 0/31 (0) - - -
* - 
Systolic BP <90 mmHg 52/271 (19.2) 7/31 (22.6) 1.23 (0.50-3.00) 0.65 - - 
Heart rate ≥125 /min 104/273 (38.1) 20/31 (64.5) 2.95 (1.36-6.41) 0.006 2.66 (1.08-6.57) 0.03 
Resp. rate ≥30 /min) 134/265 (50.6) 16/30 (53.3) 1.12 (0.52-2.38) 0.77 - - 
Oxygen satn <90 % 42/267 (15.7) 9/30 (30.0) 2.30 (0.98-5.36) 0.06 - - 
MUAC <230 mm 79/270 (29.3) 5/30 (16.7) 0.48 (0.18-1.31) 0.15 - - 
Inability to stand 41/274 (15.0) 10/31 (32.3) 2.71 (1.19-6.17) 0.02 2.63 (1.00-6.89) 0.05 
Haemoglobin <8 g/dL 38/270 (14.1) 6/31 (19.4) 1.47 (0.56-3.81) 0.43 - - 
White cell count  
<4 x 109/L 34/269 (12.7) 5/31 (16.1) 1.33 (0.48-3.70) 0.59 - 
- 
Platelets <100 x 109/L 37/270 (13.7) 6/31 (19.4) 1.51 (0.58-3.93) 0.40 - - 
Urea >7 mmol/L 83/270 (30.7) 13/31 (41.9) 1.63 (0.76-3.48) 0.21 - - 
Multilobar 
consolidation 
56/266 (21.1) 14/30 (46.7) 3.28 (1.51-7.13) 0.003 2.75 (1.17-6.47) 0.02 
Cavitation 18/274 (6.6) 2/31 (6.5) 0.98 (0.22-4.44) 0.98 - - 
Pleural effusion 98/272 (36.4) 16/31 (51.6) 1.86 (0.88-3.93) 0.10 - - 
Definition of abbreviations: BP = blood pressure; BMI = body mass index; CI = confidence interval; MUAC = mid-upper arm 
circumference; OR = odds ratio; Resp. = respiratory 
For age (in italics) data shown as median and interquartile range. Otherwise data shown as n/N (%) with variation in 
denominator compared to column header reflecting missing data. Univariable and multivariable analyses by logistic 
regression. For age, odds ratio indicates change in risk of mortality with each year increase.  
12 of 317 patients with radiographic pneumonia within study cohort excluded due to unknown 30-day outcome. Final 
multivariable analysis based on 278 patients with complete results for all included parameters.  
*Excluded from multivariable analysis because of prevalence ≤5%. 
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Supplem
ental Table E12. Accuracy of pneum
onia severity-assessm
ent tools for predicting 30-day m
ortality in hospitalised M
alaw
ian adults 
w
ith radiographic com
m
unity-acquired pneum
onia.  
Score group 
n
* 
Sensitivity %
  
(95%
 CI) 
Specificity %
 
(95%
 CI) 
PPV %
 
(95%
 CI) 
NPV %
 
(95%
 CI) 
Positive LR 
(95%
 CI) 
Negative LR 
(95%
 CI) 
AUROC 
(95%
 CI) 
CURB65 ≥3 
288 
6.7 (0.8-22.1) 
89.9 (85.6-93.3) 
7.1 (0.9-23.5) 
89.2 (84.8-92.7) 
0.66 (0.17-2.65) 
1.04 (0.94-1.15 
0.53 (0.43-0.63) 
CRB65 ≥2 
292 
20.0 (7.7-38.6) 
79.8 (74.4-84.5) 
10.2 (3.8-20.8) 
89.7 (85.1-93.3) 
0.99 (0.46-2.10) 
1.00 (0.83-1.21) 
0.50 (0.39-0.60) 
SM
RT-CO ≥2 
280 
89.7 (72.6-97.8) 
36.7 (30.7-42.9) 
14.1 (9.4-19.9) 
96.8 (91.0-99.3) 
1.42 (1.21-1.65) 
0.28 (0.10-0.84) 
0.66 (0.57-0.75) 
M
odified IDSA/ATS 
m
inor criteria ≥3 
272 
48.3 (29.4-67.5) 
72.0 (65.9-77.6) 
17.1 (9.7-27.0) 
92.1 (87.3-95.5) 
1.73 (1.13-2.64) 
0.72 (0.50-1.03) 
0.66 (0.56-0.75) 
SW
AT-Bp ≥3 
297 
40.0 (22.7-59.4) 
65.9 (59.9-71.6) 
11.7 (6.2-19.5) 
90.7 (85.7-94.4) 
1.17 (0.73-1.88) 
0.91 (0.67-1.23) 
0.54 (0.43-0.65) 
Definition of abbreviations: AUROC = area under receiver-operating characteristic curve; CI = confidence interval; CURB65 = tool based on presence of confusion, urea >7m
m
ol/L, respiratory rate 
≥30/m
in, systolic blood pressure <90m
m
Hg and/or diastolic blood pressure ≤60m
m
Hg, age ≥65 (29); CRB65 = as per CURB65 w
ith exclusion of urea (29); IDSA/ATS = m
odified version of 
Infectious Disease Society of Am
erica/Am
erican Thoracic Society criteria based on presence of respiratory rate t30/m
in, oxygen saturations d90%
 (used as a surrogate for arterial oxygen 
pressure/fraction of inspired oxygen (PaO
2 /FiO
2 ) ratio d250 criterion included in the published tool), m
ultilobar infiltrates, confusion/disorientation, urea t7.1 m
m
ol/L, w
hite blood cell count <4 
x10
9 cells/L, platelets <100 x10
9 cells/L, tem
perature <36qC, systolic blood pressure < 90 m
m
Hg (used as a surrogate for hypotension requiring aggressive fluid resuscitation; 32); LR = likelihood 
ratio; NPV = negative predictive value; PPV = positive predictive value; SM
RT-CO = tool based on presence of systolic blood pressure < 90 m
m
Hg, m
ultilobar consolidation, respiratory rate 
t25/m
in if d50 years or t30/m
in if >50 years, heart rate t125/m
in, confusion and oxygen saturations d93%
 if d50 yrs or d90%
 if >50 yrs (31); SW
AT-Bp = tool based on m
ale sex, w
asting, non-
am
bulatory status, tem
perature <35qC or >38qC and systolic blood pressure <100 m
m
Hg or diastolic blood pressure <60 m
m
Hg (28). For each tool, the perform
ance characteristics displayed are 
those using the scoring threshold for “severe CA
P” as suggested by the authors. *Score calculated in varying num
ber of patients depending on availability of results for com
ponent param
eters. 
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